<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Chemotherapy versus best supportive care for extensive small cell lung cancer - Pelayo Alvarez, M - 2013 | Cochrane Library</title> <meta content="Chemotherapy versus best supportive care for extensive small cell lung cancer - Pelayo Alvarez, M - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001990.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Chemotherapy versus best supportive care for extensive small cell lung cancer - Pelayo Alvarez, M - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001990.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001990.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Chemotherapy versus best supportive care for extensive small cell lung cancer" name="citation_title"/> <meta content="Marta Pelayo Alvarez" name="citation_author"/> <meta content="Conselleria Valenciana" name="citation_author_institution"/> <meta content="MPelayo@Hospital-Ribera.com" name="citation_author_email"/> <meta content="Virginie Westeel" name="citation_author"/> <meta content="University Hospital of Besançon" name="citation_author_institution"/> <meta content="Marcela Cortés‐Jofré" name="citation_author"/> <meta content="Programa Doctorado en Ciencias Médicas, Universidad de La Frontera" name="citation_author_institution"/> <meta content="Xavier Bonfill Cosp" name="citation_author"/> <meta content="CIBER Epidemiología y Salud Pública (CIBERESP), Spain ‐ Universitat Autònoma de Barcelona" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD001990.pub3" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/11/27" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001990.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001990.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001990.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antineoplastic Combined Chemotherapy Protocols [*therapeutic use]; Carcinoma, Small Cell [*drug therapy, mortality, pathology]; Doxorubicin [administration &amp; dosage]; Lung Neoplasms [*drug therapy, mortality, pathology]; Methotrexate [administration &amp; dosage]; Organoplatinum Compounds [administration &amp; dosage]; Randomized Controlled Trials as Topic; Survival Analysis; Topotecan [administration &amp; dosage]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001990.pub3&amp;doi=10.1002/14651858.CD001990.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001990.pub3&amp;doi=10.1002/14651858.CD001990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001990.pub3&amp;doi=10.1002/14651858.CD001990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001990.pub3&amp;doi=10.1002/14651858.CD001990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001990.pub3&amp;doi=10.1002/14651858.CD001990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001990.pub3&amp;doi=10.1002/14651858.CD001990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001990.pub3&amp;doi=10.1002/14651858.CD001990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001990.pub3&amp;doi=10.1002/14651858.CD001990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001990.pub3&amp;doi=10.1002/14651858.CD001990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001990.pub3&amp;doi=10.1002/14651858.CD001990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001990.pub3&amp;doi=10.1002/14651858.CD001990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001990.pub3&amp;doi=10.1002/14651858.CD001990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001990.pub3&amp;doi=10.1002/14651858.CD001990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001990.pub3&amp;doi=10.1002/14651858.CD001990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001990.pub3&amp;doi=10.1002/14651858.CD001990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001990.pub3&amp;doi=10.1002/14651858.CD001990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001990.pub3&amp;doi=10.1002/14651858.CD001990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001990.pub3&amp;doi=10.1002/14651858.CD001990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001990.pub3&amp;doi=10.1002/14651858.CD001990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001990.pub3&amp;doi=10.1002/14651858.CD001990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001990.pub3&amp;doi=10.1002/14651858.CD001990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001990.pub3&amp;doi=10.1002/14651858.CD001990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001990.pub3&amp;doi=10.1002/14651858.CD001990.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="STpJR8yz";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001990\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001990\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001990\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001990\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","pt","ko","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001990.pub3",title:"Chemotherapy versus best supportive care for extensive small cell lung cancer",firstPublishedDate:"Nov 27, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Lung Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=STpJR8yz&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001990.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001990.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001990.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001990.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001990.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001990.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001990.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001990.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001990.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001990.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3979 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001990.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001990.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001990.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001990.pub3/full#CD001990-abs-0006"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001990.pub3/full#CD001990-sec-0095"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001990.pub3/full#CD001990-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001990.pub3/full#CD001990-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001990.pub3/full#CD001990-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001990.pub3/full#CD001990-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001990.pub3/full#CD001990-sec-0065"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001990.pub3/full#CD001990-sec-0089"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001990.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001990.pub3/appendices#CD001990-sec-0100"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001990.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001990.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001990.pub3/media/CDSR/CD001990/table_n/CD001990StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001990.pub3/media/CDSR/CD001990/table_n/CD001990StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001990.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001990.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001990.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001990.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001990.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001990.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2013 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Chemotherapy versus best supportive care for extensive small cell lung cancer</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001990.pub3/information#CD001990-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Marta Pelayo Alvarez</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001990.pub3/information#CD001990-cr-0003">Virginie Westeel</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001990.pub3/information#CD001990-cr-0004">Marcela Cortés‐Jofré</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001990.pub3/information#CD001990-cr-0005">Xavier Bonfill Cosp</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/information/en#CD001990-sec-0105">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 27 November 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001990.pub3">https://doi.org/10.1002/14651858.CD001990.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001990-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001990-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001990-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001990-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001990-abs-0004">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD001990-abs-0003">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD001990-abs-0002">Português</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001990-abs-0001" lang="en"> <section id="CD001990-sec-0001"> <h3 class="title" id="CD001990-sec-0001">Background</h3> <p>Combination chemotherapy has been the mainstay of treatment for extensive stage small celI lung cancer (SCLC) over the last 30 years, even though it only gives a short prolongation in median survival time. The main goal for these patients should be palliation with the aim of improving their quality of life. </p> </section> <section id="CD001990-sec-0002"> <h3 class="title" id="CD001990-sec-0002">Objectives</h3> <p>To determine the effectiveness of first‐line chemotherapy versus placebo or best supportive care (BSC) in prolonging survival in patients with extensive SCLC at diagnosis and the effectiveness of second‐line chemotherapy at relapse or progression after first‐line chemotherapy compared with BSC or placebo in prolonging survival in patients with extensive SCLC; as well as to evaluate the adverse events of treatment and the quality of life of patients. </p> </section> <section id="CD001990-sec-0003"> <h3 class="title" id="CD001990-sec-0003">Search methods</h3> <p>This is the second update of the review. MEDLINE (1966 to October 2013), EMBASE (1974 to October 2013), and the Cochrane Central Register of Controlled Trials (CENTRAL) (2012, Issue 3) were searched. Experts in the field were contacted. </p> </section> <section id="CD001990-sec-0004"> <h3 class="title" id="CD001990-sec-0004">Selection criteria</h3> <p>Phase III randomised controlled trials in which any chemotherapy treatment was compared with  placebo or BSC in patients with extensive SCLC, as first‐line or second‐line therapy at relapse. </p> </section> <section id="CD001990-sec-0005"> <h3 class="title" id="CD001990-sec-0005">Data collection and analysis</h3> <p>Two authors independently extracted data and assessed study quality. We resolved disagreements by discussion. Additional information was obtained from one study author. </p> </section> <section id="CD001990-sec-0006"> <h3 class="title" id="CD001990-sec-0006">Main results</h3> <p>Two studies of unclear risk of bias were included for first‐line chemotherapy. A total of 88 men under 70 years with good performance status were randomised to receive either supportive care, placebo infusion or ifosfamide. Ifosfamide gave an extra mean survival of 78.5 days compared with supportive care or placebo infusion. Partial tumour response was greater with the active treatment. Toxicity was only seen in the chemotherapy group and quality of life was only assessed at the beginning of treatment. The quality of the evidence for overall survival and adverse effects was very low. </p> <p>Three studies of moderate risk of bias were included for second‐line chemotherapy at relapse (one identified in the last search). A total of 932 men and women under 75 years and any performance status were randomised to receive either methotrexate‐doxorubicin, topotecan, or picoplatin versus symptomatic treatment or BSC. The methotrexate‐doxorubicin treatment gave a median survival of 63 days longer than in the symptomatic‐treatment group for patients allocated to receive four cycles of first‐line chemotherapy, and 21 days longer for patients allocated to receive eight cycles of first‐line chemotherapy. </p> <p>Treatment with topotecan gave a median survival of 84 days longer than in the BSC group (log‐rank P = 0.01). The adjusted hazard ratio (HR) for overall survival was 0.61 (95% CI 0.43 to 0.87). Treatment with picoplatin gave a median survival time of six days longer than BSC (HR 0.817, 95% CI 0.65 to 1.03, P = 0.0895). A meta‐analysis of topotecan and picoplatin gave a HR of 0.73 (95% CI 0.55 to 0.96, P = 0.03; low‐quality evidence). </p> <p>Partial or complete response in the methotrexate‐doxorubicin group was 22.3%. Five patients (7%, 95% CI 2.33 to 15.67) showed a partial response with topotecan. No data were provided about tumour response in the picoplatin study. Toxicity was worst in the chemotherapy group (moderate‐quality evidence). Quality of life was better in the topotecan group and was not measured in the methotrexate‐doxorubicin and picoplatin studies (low‐quality evidence). </p> </section> <section id="CD001990-sec-0007"> <h3 class="title" id="CD001990-sec-0007">Authors' conclusions</h3> <p> Two small RCTs from the 1970s suggest that first‐line chemotherapeutic treatment (based on ifosfamide) may provide a small survival benefit (less than three months) in comparison with supportive care or placebo infusion in patients with advanced SCLC. However platinum‐based combination chemotherapy regimens have been shown to increase complete response rates when compared to non‐platinum chemotherapy regimens with no significant difference in survival, and so these are currently the standard first‐line treatment for patients with SCLC. </p> <p>Second‐line chemotherapy at relapse or progression may prolong survival for some weeks in relation to BSC. Nevertheless, the impact of first‐line chemotherapy on quality of life, older patients, women and patients with poor prognosis is unknown and the benefits of second‐line chemotherapy are also unclear for older people. Globally, the evidence on which these conclusions are based is very scarce and of uncertain or low quality, which calls for well‐designed, controlled trials to further evaluate the trade‐offs between benefits and risks of different chemotherapeutic schedules in patients with advanced SCLC. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001990-abs-0006" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001990-abs-0006">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001990-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001990-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001990-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD001990-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD001990-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD001990-abs-0007">Português</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001990-abs-0006" lang="en"> <h3>Chemotherapy (anticancer drugs) for patients with advanced small cell lung cancer</h3> <p>SmalI cell lung cancer accounts for nearly a quarter of all new cases of lung cancer. This cancer is often diagnosed in an advanced stage, which means that it has spread to the brain, liver, bone or bone marrow, and most patients die in the first year after diagnosis. This review found that first‐line chemotherapy (anticancer drugs) may prolong the survival of patients with advanced small cell lung cancer for some months when compared to supportive care, although the effect of this treatment on quality of life is unknown. The benefit of a new treatment (second‐line chemotherapy) when the disease has progressed or relapsed was even smaller, and the potential survival gain of some weeks must be balanced against its possible secondary effects. Since the available studies were scarce and of variable quality, more clinical trials are needed to assess and better inform patients about the real effectiveness of chemotherapy in advanced small cell lung cancer. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001990-sec-0095" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001990-sec-0095"></div> <h3 class="title" id="CD001990-sec-0096">Implications for practice</h3> <section id="CD001990-sec-0096"> <p>SCLC is an aggressive and fatal disease in the short term. Two small RCTs from the 1970s suggest that first‐line chemotherapy treatment (based on ifosfamide) may provide a small survival benefit (less than three months) in comparison with supportive care or placebo infusion in patients with advanced SCLC, particularly those younger than 70 years with good performance status. The benefits remain unclear in older patients, women, and patients with poor performance status. However platinum‐based combination chemotherapy regimens have been shown to increase complete response rates when compared to non‐platinum chemotherapy regimens with no significant difference in survival, and so these are currently the standard first‐line treatment for patients with SCLC. </p> <p>Second‐line chemotherapy (based on topotecan) at relapse or on progression could increase survival by a few weeks in patients with no symptomatic brain metastases and any performance status compared to best supportive care (BSC). Its benefits remains unclear in women, patients with a treatment‐free interval ≤60 days after first‐line chemotherapy and in patients with liver metastases. </p> <p>Globally, the evidence on which these conclusions are based is very scarce and of uncertain or low quality, so it would be necessary to explain to patients the weak evidence for any benefit attributable to chemotherapy as well the poor prognosis of the disease in the short term, in a way that is understandable by them, in order to avoid inaccurate expectations. </p> </section> <h3 class="title" id="CD001990-sec-0097">Implications for research</h3> <section id="CD001990-sec-0097"> <p>Since chemotherapy with more modern agents is now established treatment for patients with SCLC, it is likely that a new study comparing active chemotherapy with BSC would be considered unethical. New studies comparing different drugs or combinations could be undertaken, with ifosfamide as the necessary comparator. The feasibility and ethics of conducting studies comparing active treatment with BSC in patients with poor prognosis (with poor performance status, women, or older people) could also be considered. This would allow the setting of more clear and explicit criteria to guide when to stop chemotherapy, with the objective of preserving quality of life. </p> <p>In patients with SCLC that has relapsed or progressed, the uncertainty about the trade‐offs between potential benefits (a gain of some weeks in survival), probable toxicity, and associated costs, coupled with the paucity and dubious quality of the available studies, would justify more trials comparing second‐line chemotherapy versus BSC. These randomised clinical trials should be well‐designed and large enough to allow assessment of the benefits in pre‐specified subgroups such as women, older patients, people with low performance status, and previous response to first‐line chemotherapy. These trials should also evaluate the effectiveness of follow‐up schedules after first‐line chemotherapy and include the use of validated instruments to measure quality of life. In addition, the information provided by the new, studies could be presented to patients and relatives in some objective way to enable them to make well‐informed decisions on the potential risks and benefits of available therapeutic options. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001990-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001990-sec-0036"></div> <div class="table" id="CD001990-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">First‐line chemotherapy compared with BSC for extensive SCLC</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>First‐line chemotherapy compared with BSC for extensive SCLC</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: patients</b> with extensive SCLC without previous treatment </p> <p><b>Settings: one hospital in Vienna</b> </p> <p><b>Intervention: first‐line chemotherapy</b> </p> <p><b>Comparison: Supportive treatment</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Supportive care</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>First‐line chemotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean survival ranged across control groups from<br/> 56‐93 days <sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean survival in the intervention groups was<br/> 134‐172 days <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Haematological: 0%</p> <p>Leucopenia:0%</p> <p>Vomiting and hair loss: 0%</p> <p>Other: 0%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Haematological:   94.1%</p> <p>Leucopenia:15% ifosfamide; 15.8% ifosfamide + CCNU</p> <p>Vomiting and hair loss: 70% ifosfamide; 68.4% ifosfamide + CCNU</p> <p>Other: 55% ifosfamide; 52.6% ifosfamide + CCNU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. The corresponding median survival time in extensive SCLC in the control and intervention groups has been obtained from Kokron 1977 and Kokron 1982 </p> <p>2. Significant risk of bias across the studies</p> <p>3. Small sample sizes across the studies</p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001990-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Second‐line chemotherapy at relapse or progression in extensive SCLC</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Second‐line chemotherapy compared with BSC for extensive SCLC</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: patients</b> with extensive SCLC who relapsed or progressed after first‐line chemotherapy </p> <p><b>Settings: multi‐institutional‐multicentre</b> </p> <p><b>Intervention: second‐line chemotherapy</b> </p> <p><b>Comparison: BSC</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>BSC</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Second‐line chemotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median survival ranged across control groups from 97.3‐138 days<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median survival in the intervention groups was 144‐181.3 days<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0.73</p> <p>(0.55, 0.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>542</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Toxic death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6% topotecan</p> <p>0% picoplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>542</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Dyspnoea 3%</p> <p>Fatigue 4%</p> <p>Non sepsis infection 12%</p> <p>sepsis 1%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Haematological: 18%‐61% neutropenia, 38%‐41% Thrombocytopenia, 25%‐29% anaemia,</p> <p>Non sepsis infection 14%</p> <p>Sepsis 4%</p> <p>Asthenia 11%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>542</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See footnotes 3</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See footnotes 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Difference in rate of deterioration per 3‐month intervals in the EQ‐5D score: 0.15 (95% CI 0.05, 0.25) </p> <p>In the PSA questionnaire:</p> <p>shortness of breath RR: 2.18 (1.09 to 4.38)</p> <p>interference with sleep RR: 2.16 (1.15 to 4.06)</p> <p>fatigue RR: 2.29 (1.25 to 4.19)<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>4,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>BSC:</b> best supportive care; <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>HR</b>: hazard ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. The corresponding median survival time in extensive SCLC in the control group has been obtained from O'Brien 2006 and Ciuleanu 2010 </p> <p>2. The corresponding median survival time in extensive SCLC in the intervention group has been obtained from O'Brien 2006 and Ciuleanu 2010 </p> <p>3. The difference in rate of deterioration was obtained through the EQ‐5D (EuroQol‐5‐Dimensions Health) questionnaire, consisting of five health status dimensions: mobility, self‐care, usual activities, pain and discomfort, anxiety and depression, with rating of 1 (no problem) to 3 (extreme problem). Patients were evaluated before each course of second‐line chemotherapy, or at each visit in the BSC arm. </p> <p>The PSA (Patient Self Assessment) questionnaire rating scale for severity is from 1 (not at all), to 4 (very much) </p> <p>4. Some significant risk of bias across the studies</p> <p>5. Some significant risk of other bias in one study</p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001990-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001990-sec-0037"></div> <section id="CD001990-sec-0038"> <h3 class="title" id="CD001990-sec-0038">Description of the condition</h3> <p>Small cell Iung cancer (SCLC) accounts for 15% to 17% of new cases of lung cancer among males and females respectively (<a href="./references#CD001990-bbs2-0084" title="RiazPS , LüchtenborgM , CouplandHV , SpicerJ , PeakeDM , MollerH . Trends in incidence of small cell lung cancer and all lung cancer. Lung Cancer2012;75:280‐4. ">Riaz 2012</a>), with a gradual decline in the proportion of male patients compared to female patients in the last two decades. Women comprised 28% of all cases in 1973 yet by 2002 this proportion had risen to 50% (<a href="./references#CD001990-bbs2-0093" title="Wheatley‐PriceP , MaC , AshcroftLF , NankivellM , StephensRJ , WhiteSC , et al. The strength of female sex as prognostic factor in small‐cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit. Annals of Oncology2010;21:232‐7. ">Weatley‐Price 2010</a>). As a result of increasing life expectancy, about 32% of newly diagnosed SCLC cases occur in patients older than 70 years of age and 10% of cases are diagnosed in patients older than 80 years of age (<a href="./references#CD001990-bbs2-0081" title="OwonikokoTK , RaginCC , BelaniChP , OtonAB , GoodingWE , TaioliE , et al. Lung cancer in elderly patients: an analysis of the Surveillance, Epidemiology, and End Results Database. Journal of Clinical Oncology2007;25:5570‐7. ">Owonikoko 2007</a>). Early diagnosis of SCLC is uncommon. Between 60% and 70% of patients have extensive disease at diagnosis with metastases involving one or more sites, such as the brain, liver, bone or bone marrow (<a href="./references#CD001990-bbs2-0058" title="CarneyD . Lung cancer ‐ Time to move on from chemotherapy. New England Journal of Medicine2002;346:126‐7. ">Carney 2002</a>). Untreated SCLC is lethal within two to three months of diagnosis in most patients, and survival beyond one year is rare (<a href="./references#CD001990-bbs2-0064" title="DeVitaV , HellanS , RosembergS . Cancer: Principles &amp; Practice of Oncology. Sixth. Philadelphia: Lippincott, 2000. ">De Vita 2000</a>; <a href="./references#CD001990-bbs2-0092" title="VrdoljakE , MiseK , SapunarA , RozgaA , MarusicM . Staging in untreated patients with small cell Iung cancer. Neoplasma2001;48:154‐6. ">Vrdoljak 2001</a>; <a href="./references#CD001990-bbs2-0096" title="ZelenM . Keynote address on biostatistics and data retrieval. Cancer Chemotherapy Reports. Part 31973;4:31‐42. ">Zelen 1973</a>). The majority of patients with extensive disease will relapse after treatment, usually within the first year after diagnosis. The two‐year cumulative recurrence rate is 75% in patients with limited disease and nearly 100% in patients with extensive disease. The lungs are the most frequent site of initial recurrence, followed by the liver, bone, and the brain (<a href="./references#CD001990-bbs2-0068" title="GrallaRJ . Quality of life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life. The Oncologist2004;9 Suppl 6:14‐24. ">Gralla 2004</a>; <a href="./references#CD001990-bbs2-0090" title="SugiyamaT , HiroseT , HosakaT , KusumotoS , NakashimaM , YamaokaT , et al. Effectiveness of intensive follow‐up after response in patients with small cell lung cancer. Lung Cancer2008;59:255‐61. ">Sugiyama 2008</a>). Local treatments such as resection and radiotherapy have a limited effect on advanced disease (<a href="./references#CD001990-bbs2-0089" title="SouhamiRL , LawK . Longevity in small cell lung cancer. A report to the Lung Cancer SubCommitee of the United Kingdom Coordinating Commitee for Cancer Research. British Journal of Cancer1990;61:584‐9. ">Souhami 1990</a>) so the most widely accepted option for treating advanced SCLC is chemotherapy. Current evidence does not support screening for lung cancer with any modality, including chest radiography, sputum cytology, or spiral computed tomography (<a href="./references#CD001990-bbs2-0079" title="ManserR , IrvingLB , StoneC , ByrnesG , AbramsonMJ , CampbellD . Screening for lung cancer. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD001991.pub2] ">Manser 2010</a>). There is no evidence either for recommending vitamin supplements for the prevention of lung cancer (<a href="./references#CD001990-bbs2-0062" title="Cortés JofréM , RuedaJR , Corsini‐MuñozG , Fonseca‐CortésC , CarballosoM , Bonfill CospX . Drugs for preventing lung cancer in healthy people. Cochrane Database of Systematic Reviews2012, Issue 10. [DOI: 10.1002/14651858.CD002141.pub2] ">Cortés‐Jofré 2012</a>). </p> <p>The effect of chemotherapy with single agents was evaluated in controlled studies by the Veteran Administration Lung Group, which showed the effectiveness of cyclophosphamide in the treatment of SCLC when compared with placebo (<a href="./references#CD001990-bbs2-0023" title="GreenR , HumphreyE , CloseH , PatnoM . Alkylating Agents in Bronchogenic Carcinoma. American Journal of Medicine1969;46:516‐25. ">Green 1969</a>). Following on from these studies, combination chemotherapy became the mainstay of treatment for patients with extensive‐stage SCLC in the 1970s (<a href="./references#CD001990-bbs2-0072" title="IhdeDC . Chemotherapy of lung cancer. New England Journal of Medicine1992;327:1434‐41. ">Ihde 1992</a>). In the 1980s, the most widely used combination of drugs for initial treatment of extensive‐stage SCLC was cyclophosphamide, doxorubicin, and vincristine, which produced partial or complete tumour remissions in 50% to 85% of patients and increased the median survival time by between nine and 12 months in unselected patient groups (<a href="./references#CD001990-bbs2-0065" title="DeWetM , FalksonG , RapoportBL . Small cell Iung cancer: analysis of factors influencing the response to treatment and survival. Oncology1994;51:523‐34. ">De Wet 1994</a>; <a href="./references#CD001990-bbs2-0070" title="HollenPi , GrallaRJ , KrisMG , CoxC , BelaniCP , GrunbergSM , et al. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. Cancer1994;73:2087‐98. ">Hollen 1994a</a>; <a href="./references#CD001990-bbs2-0071" title="HollenPi , GrallaRJ , KrisMG , CoxC . Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS). Supportive Care in Cancer1994;2:213‐22. ">Hollen 1994b</a>; <a href="./references#CD001990-bbs2-0082" title="OzeI , HottaK , KiuraK , OchiN , TakigawaN , FujiwaraY , et al. Twenty‐seven years of phase III trials for patients with extensive disease small‐cell lung cancer: disappointing results. PLOS ONE2009;4:e7835. ">Oze 2009</a>; <a href="./references#CD001990-bbs2-0089" title="SouhamiRL , LawK . Longevity in small cell lung cancer. A report to the Lung Cancer SubCommitee of the United Kingdom Coordinating Commitee for Cancer Research. British Journal of Cancer1990;61:584‐9. ">Souhami 1990</a>). In the late 1980s, a combination regime of cisplatin and etoposide was introduced. Despite diverse strategies for the treatment of these patients, the results of phase III trials over the past 30 years have shown only a two month prolongation in median survival time for patients treated with different regimens (<a href="./references#CD001990-bbs2-0060" title="ChuteJ , ChenT , FeigalE , SimonR , JohnsonB . Twenty years of phase III trials for patients with extensive‐stage small celI lung cancer: perceptible progress. Journal of Clinical Oncology1999;17:1794‐801. ">Chutte 1999</a>), or a 0.021 month (0.63 day) increase in median survival time per year (<a href="./references#CD001990-bbs2-0082" title="OzeI , HottaK , KiuraK , OchiN , TakigawaN , FujiwaraY , et al. Twenty‐seven years of phase III trials for patients with extensive disease small‐cell lung cancer: disappointing results. PLOS ONE2009;4:e7835. ">Oze 2009</a>), with 5% to 10% surviving two years and only 1% of patients achieving long‐term disease‐free survival (<a href="./references#CD001990-bbs2-0067" title="GovindanR , PageN , MorgenszternD , ReadW , TierneyR , VlahiotisA , et al. Changing epidemiology of small‐cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. Journal of Clinical Oncology2006;24:4539‐44. ">Govindan 2006</a>; <a href="./references#CD001990-bbs2-0026" title="HannaNH , SandlerAB , LoehrerPJ , AnsariR , JungSH , laneK , et al. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small‐cell lung cancer: a Hoosier Oncology Group randomised study. Annals of Oncology2002;13:95‐102. ">Hanna 2002</a>; <a href="./references#CD001990-bbs2-0076" title="Lassen , HirschFR , OsterlindK , BergmanB , DombernoswkyP . Outcome of combination chemotherapy in extensive stage small‐celI lung cancer: any treatment related progress?. Lung Cancer1998;20:151‐60. ">Lassen 1998</a>; <a href="./references#CD001990-bbs2-0095" title="WolfM , TebbeS , FinkT . First‐line chemotherapy in metastatic small‐cell lung cancer (SCLC). Lung Cancer2004;Suppl 2:S223‐34. ">Wolf 2004</a>). Overall, women have had a significantly longer median survival than men (<a href="./references#CD001990-bbs2-0093" title="Wheatley‐PriceP , MaC , AshcroftLF , NankivellM , StephensRJ , WhiteSC , et al. The strength of female sex as prognostic factor in small‐cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit. Annals of Oncology2010;21:232‐7. ">Weatley‐Price 2010</a>). The lowest survival rates are in the very elderly, 80 years or older (<a href="./references#CD001990-bbs2-0081" title="OwonikokoTK , RaginCC , BelaniChP , OtonAB , GoodingWE , TaioliE , et al. Lung cancer in elderly patients: an analysis of the Surveillance, Epidemiology, and End Results Database. Journal of Clinical Oncology2007;25:5570‐7. ">Owonikoko 2007</a>). </p> <p>A large number of clinical trials comparing different regimens, schedules, and dose intensities of agents have been conducted in advanced SCLC. Comparator regimens have varied greatly between trials, not only with respect to agents but also in dosage, scheduling, and patient and disease factors. The assimilation of findings from this large range of heterogeneous trials is therefore difficult. To date no consistent findings have emerged as to the optimal agent combination or as to the effectiveness of increased dose intensity (<a href="./references#CD001990-bbs2-0058" title="CarneyD . Lung cancer ‐ Time to move on from chemotherapy. New England Journal of Medicine2002;346:126‐7. ">Carney 2002</a>). Recommended treatment regimens have varied with time and at present combinations of platinum are most often indicated for advanced disease (<a href="./references#CD001990-bbs2-0087" title="SeidenfeldJ , Samson DJ , BonnellCJ , ZieglerKM , AronsonN . Management of small cell lung cancer. Evidence Report/Technology Assessment No 143. AHRQ Publication No. 06‐E016. Rockville, MD: Agency for Health Research and QualityJuly 2006. ">Seidenfeld 2006</a>). A recent systematic review of platinum versus non‐platinum chemotherapy regimens for SCLC did not find a statistically significant benefit in survival or overall tumour response for platinum‐based therapy (<a href="./references#CD001990-bbs2-0055" title="AmarasenaIU , WaltersJAE , Wood‐BakerR , FongK . Platinum versus non‐platinum chemotherapy regimens for small cell lung cancer. Cochrane Database of Systematic Reviews2008, Issue 4. [DOI: 10.1002/14651858.CD006849.pub2] ">Amarasena 2009</a>). However, platinum‐based chemotherapy regimens did increase complete response rates, at the cost of higher adverse events. Patients treated with chemotherapy can be categorized as having refractory disease where the disease progresses through first‐line treatment; resistance disease, which includes those patients with an initial response to treatment but the disease then progresses within three months of completing treatment; and sensitive disease where patients who have a relapse‐free interval of at least three months from completion of treatment receive re‐treatment with first‐line therapy as the standard approach (<a href="./references#CD001990-bbs2-0021" title="GarassinoMC , TorriV , MichettiG , Lo DicoM , LaVerdeN , SglioneS , et al. Outcomes of small‐cell lung cancer patients treated with second‐line chemotherapy: A multi‐institutional retrospective analysis. Lung Cancer2011;72:378‐83. ">Garassino 2011</a>). Second‐line chemotherapy offered to patients at relapse may produce tumour regression but the evidence for a clinical benefit is limited. The degree of benefit seems to be related to the type of first‐line chemotherapy used, the length of the treatment‐free interval, the extent of disease at relapse, and the performance status of the individual (<a href="./references#CD001990-bbs2-0091" title="Sundstr¢mS , BremnesRM , KaasaS , Aaseb¢U , AamdalS . Second‐line chemotherapy in recurrent small lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP‐regimen) or cyclophosphamide, epirubicin, and vincristin (CEV‐regimen). Lung Cancer2005;48:251‐61. ">Sundstr¢m 2005</a>).Thus, until better treatments are developed, the main goal of the therapy for extensive‐stage SCLC should be adequate palliation and improvement of overall quality of life. </p> <p>Our purpose was to review the evidence for the effectiveness of first‐line and second‐line chemotherapy at relapse or progression in extensive disease SCLC. This is the second update of the review. </p> </section> <section id="CD001990-sec-0039"> <h3 class="title" id="CD001990-sec-0039">Description of the intervention</h3> <p>The purpose of this review was to evaluate the effectiveness of first‐line chemotherapy and second‐line chemotherapy at relapse or progression after first‐line chemotherapy in patients with extensive SCLC compared with best supportive care (BSC) or placebo treatment. </p> </section> <section id="CD001990-sec-0040"> <h3 class="title" id="CD001990-sec-0040">How the intervention might work</h3> <p>Benefits of first‐line or second‐line chemotherapy in advanced SCLC patients should include a significantly longer survival than for those treated with best supportive care (BSC) or placebo. The significant improvement in survival should be accompanied by manageable toxicity and an improvement or stabilisation in the quality of life. </p> </section> <section id="CD001990-sec-0041"> <h3 class="title" id="CD001990-sec-0041">Why it is important to do this review</h3> <p>This review of first‐line chemotherapy compared with BSC or placebo treatment and second‐line chemotherapy at relapse or progression after first‐line chemotherapy is the second update of a previous review conducted in 2003 (<a href="./references#CD001990-bbs2-0097" title="Agra VarelaY , Pelayo AlvarezM , SacristanM , Sacristan RodeaA , SerraC , Bonfill CospX . Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database of Systematic Reviews2003, Issue 4. [DOI: 10.1002/14651858.CD001990] ">Agra 2003</a>) and updated in 2009 (<a href="./references#CD001990-bbs2-0098" title="Pelayo AlvarezM , Gallego RubioO , Bonfill CospX , Agra VarelaY . Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD001990.pub2] ">Pelayo 2009</a>). After completion of the original review several questions were raised about future research into the benefits of chemotherapy in extensive SCLC. It was suggested that the feasibility and ethics of undertaking studies comparing active treatment with BSC in patients with poor prognosis should be evaluated. Consideration of the risks and benefits of first and second‐line chemotherapy in this subgroup of patients would help to define clearer and more explicit criteria about when to stop chemotherapy or when not to administer second‐line treatment with the objective of preserving quality of life. Therefore, the focus of this review is to evaluate chemotherapy compared with BSC in patients with poor prognosis that present with extensive disease at diagnosis or have experienced relapse or progression after first‐line treatment. All are patients with an extremely low short‐term survival rate. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001990-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001990-sec-0042"></div> <p>1. To determine the effectiveness of first‐line chemotherapy versus placebo or best supportive care (BSC) in prolonging survival in patients with extensive SCLC at diagnosis. </p> <p>2. To determine the effectiveness of second‐line chemotherapy at relapse or progression after first‐line chemotherapy compared with BSC or placebo in prolonging survival in patients with extensive SCLC. </p> <p>3. To evaluate the adverse events of treatment as well as the quality of life of patients with extensive SCLC who were treated with first or second‐line chemotherapy. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001990-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001990-sec-0043"></div> <section id="CD001990-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001990-sec-0045"> <h4 class="title">Types of studies</h4> <p>Phase III randomised controlled trials in patients with extensive stage SCLC. Studies were eligible for inclusion if they were described by the authors as ‘randomised’ anywhere in the manuscript.<br/> There was no language restriction in considering studies eligible for the review. </p> <p>We excluded phase I and phase II randomised controlled trials.</p> </section> <section id="CD001990-sec-0046"> <h4 class="title">Types of participants</h4> <p>Patients of any age with histologically proven SCLC carcinoma staged as extensive or metastatic disease after completion of clinical and diagnostic staging studies. Extensive or metastatic SCLC cancer means that the tumour has spread beyond one hemithorax, including the ipsilateral mediastinal and supraclavicular fossa lymph nodes. All patients with distant metastases were considered to have extensive‐stage disease. </p> <p>For studies of first‐line chemotherapy, patients that were included were those that had not received previous treatment (chemotherapy, radiotherapy, hormonal treatment, growth factor, immunotherapy, surgery). For studies of second‐line chemotherapy, patients were included if they had received previous chemotherapy treatment and after relapse or progression they received a different chemotherapy regimen. Patients who had received previous radiotherapy, surgery, hormonal treatment, growth factor, or immunotherapy were excluded. </p> </section> <section id="CD001990-sec-0047"> <h4 class="title">Types of interventions</h4> <p>Studies in which any chemotherapy regimen (any single agent or combination of agents, at any dosage, for any duration or number of cycles) was compared with a control group who received placebo or BSC, and in which there was no concomitant or sequential radiotherapy with curative intention. BSC measures included pain medications and other non‐specific palliative treatments (including radiotherapy with explicitly palliative intention, &lt;5 0 Gy) that were intended to palliate a particular symptom. </p> <p>We excluded studies in which any anticancer treatment other than chemotherapy (radiotherapy or chemoradiotherapy, surgery, hormonal treatment, growth factors, immunotherapy) was compared with either BSC or a placebo intervention. </p> </section> <section id="CD001990-sec-0048"> <h4 class="title">Types of outcome measures</h4> <section id="CD001990-sec-0049"> <h5 class="title">Primary outcomes</h5> <p>I) Overall survival, measured as the hazard ratio or median or mean values with confidence intervals </p> </section> <section id="CD001990-sec-0050"> <h5 class="title">Secondary outcomes</h5> <p>II) Survival at 6,12, 24 months</p> <p>III) Complete* and partial** response (see below)</p> <p>IV) Toxicity, toxic deaths and any other measures of toxicity found to be recorded consistently across studies </p> <p>V) Quality of life</p> <p>* Complete response: total disappearance of all known disease for a period of at least four weeks. </p> <p>** Partial response: in the case of bi‐dimensionally measurable disease, a reduction of at least 50% in the sum of the products of the greatest perpendicular diameters measurable or of alI measurable lesions, determined through two observations not more than four weeks apart; in the case of uni‐dimensionally measurable disease, reduction of at least 50% in the sum of the greatest diameters of all lesions determined through two observations not more than four weeks apart. </p> </section> </section> </section> <section id="CD001990-sec-0051"> <h3 class="title">Search methods for identification of studies</h3> <p>All randomised clinical trials and controlled clinical trials on this subject were searched for electronically using MEDLINE (1966 to October 2013), EMBASE (1974 to October 2013), and the Cochrane Central Register of Controlled Trials (CENTRAL) (2012, Issue 3). </p> <section id="CD001990-sec-0052"> <h4 class="title">Electronic searches</h4> <p>The electronic searches are detailed in <a href="./appendices#CD001990-sec-0101">Appendix 1</a>. </p> </section> <section id="CD001990-sec-0053"> <h4 class="title">Searching other resources</h4> <p>1. Identification of further studies from references cited in the initial list of articles </p> <p>2. We contacted pharmaceutical companies to identify any further unpublished or ongoing trials </p> <p>3. A search of ongoing trials on the world‐wide web: <a href="http://www.controlled-trials.com" target="_blank">www.controlled‐trials.com</a> and <a href="http://www.cancer.gov" target="_blank">www.cancer.gov</a> </p> <p>4. A search of grey literature on the world‐wide web: <a href="http://cadth.ca/resources/grey-matters" target="_blank">http://cadth.ca/resources/grey‐matters</a> </p> </section> </section> <section id="CD001990-sec-0054"> <h3 class="title" id="CD001990-sec-0054">Data collection and analysis</h3> <section id="CD001990-sec-0055"> <h4 class="title">Selection of studies</h4> <p>Two authors independently assessed the abstracts of all references identified from the search strategy for inclusion and resolved any disagreements by discussion. We excluded abstracts referring exclusively to limited disease or treatments other than chemotherapy compared with placebo or BSC. </p> </section> <section id="CD001990-sec-0056"> <h4 class="title">Data extraction and management</h4> <p>We entered the trials that met the selection criteria in a specific database. Foreign papers were translated when necessary to allow full assessment. Two authors independently extracted the data from the included studies using a previously standardised and tested form. We resolved discrepancies by discussion. Because most of the studies retrieved by the searches included both patients with limited and extensive disease, we sought specific information about patients with extensive disease from the principal investigators. </p> <p>To assess the quality of each study we entered the following data in to the database.</p> <p> <ul id="CD001990-list-0001"> <li> <p>Randomisation methods and allocation concealment.</p> </li> <li> <p>Participants: description of patients, age, sex, and performance status.</p> </li> <li> <p>Previous treatment.</p> </li> <li> <p>Interventions: types of drugs and doses, cycles and frequency, other concomitant or sequential treatment, and time of follow‐up. </p> </li> <li> <p>Blinding strategies in the follow‐up and assessment of the results.</p> </li> <li> <p>Losses to follow‐up and use or not of an intention‐to‐treat analysis.</p> </li> <li> <p>Sample size and how this was determined.</p> </li> <li> <p>Statistical analysis performed.</p> </li> <li> <p>Baseline data.</p> </li> <li> <p>Outcomes: survival time (medians or means at different periods and confidence intervals), complete and partial tumour responses, drug toxicity, and quality of life. </p> </li> </ul> </p> </section> <section id="CD001990-sec-0057"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed bias in accordance with The Cochrane Collaboration's tool for assessing risk of bias (<a href="./references#CD001990-bbs2-0069" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011].. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). For each study we considered the following. </p> <p> <ul id="CD001990-list-0002"> <li> <p>Selection bias: systematic differences between baseline characteristics of the comparison groups. </p> </li> </ul> </p> <p>‐ <b>Sequence generation</b>: a description for allocating interventions to participants based on a random process. </p> <p>* Low risk of bias: the authors describe a random component in the sequence generation process </p> <p>* High risk of bias: the authors describe a non‐random component in the sequence generation process </p> <p>* Unclear: there is insufficient information about the sequence generation process to permit judgement of "Low risk" or "High risk" </p> <p>‐ <b>Allocation concealment</b>: a description of any method to secure implementation of the random assignments to prevent that allocations could have been foreseen. </p> <p>* Low risk of bias: the authors describe a central allocation, or sequentially numbered of identical appearance, or sealed envelopes opaque and numbered </p> <p>* High risk of bias: there is a description of open random allocation, or unsealed or non‐opaque envelopes, or alternation, or date of birth </p> <p>* Unclear: there is insufficient information about the method of concealment to permit judgement of "Low risk" or "High risk" </p> <p> <ul id="CD001990-list-0003"> <li> <p>Performance bias: systematic differences between groups in the care provided or in other factors different from the intervention. </p> </li> </ul> </p> <p>‐<b>Blinding of participants and personnel</b>: a description of measures used to blind study participants and personnel for knowledge of which intervention a participant received. Description of any evaluation of effective blinding was also considered. Blinding was considered important for the outcomes of tumour response, toxicity and quality of life, and less important for survival. </p> <p>* Low risk of bias: blinding of participants and personnel and unlikely that could have been broken, or no blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influence by lack of blinding </p> <p>*High risk of bias: blinding of participants and personnel and likely that the blinding could have been broken with the outcome likely to be influenced by lack of blinding, or no blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding </p> <p>* Unclear: there is insufficient information to permit judgement of "Low risk" or "High risk", or the study did not address blinding </p> <p>‐<b>Blinding of outcome assessors</b>: a description of measures used to blind the assessment of the outcomes </p> <p>*Low risk of bias: blinding of the outcome assessment and unlikely that the blinding could have been broken, or no blinding but the review authors considered that the outcome measurement is not likely to be influence by lack of blinding </p> <p>*High risk of bias: blinding of the outcome assessment and likely that the blinding could have been broken with the outcome measurement likely to be influenced by lack of blinding, or no blinding when the outcome assessment is likely to be influence by lack of blinding </p> <p>*Unclear: there is insufficient information to judge the existence of "Low risk" or "High risk" or the study did not address this kind of blinding </p> <p> <ul id="CD001990-list-0004"> <li> <p>Attrition bias: systematic differences between groups in withdrawals form the study.</p> </li> </ul> </p> <p>‐ <b>Incomplete outcome data</b>: a description of the level of completeness of each outcome, including withdrawals, dropouts, and protocol deviations. Number of randomised patients in each group and number of evaluated patients with reasons for attrition reported. </p> <p>*Low risk of bias: any one of the following. No missing outcome data; missing outcome data balanced in number across groups, with similar reasons for missing data; the proportion of missing outcomes compared with the observed event risk is not enough to have a clinically relevant impact on the intervention effect estimate </p> <p>*High risk of bias: there is reason for missing outcome data likely to be related to the true outcome, with either imbalance in numbers or in reasons for missing data across groups; the proportion of missing outcomes compared with the observed event risk is enough to produce clinically relevant bias in the intervention effect estimate; "as‐treated" analysis done with substantial departure of the intervention received form that assigned at randomisation. </p> <p>*Unclear: there is insufficient information of attrition/exclusions to permit judgement of "Low risk" or "High risk" </p> <p> <ul id="CD001990-list-0005"> <li> <p>Reporting bias: reporting a selection of a subset of the original outcome variables</p> </li> </ul> </p> <p>‐<b>Selective reporting</b>: </p> <p>*Low risk of bias: any one of the following. The study protocol is available and all of the study's prespecified outcomes that are of interest in the review have been reported or the study protocol is not available but it is clear that the published report include all expected outcomes, including those that were prespecified </p> <p>*High risk of bias: not all of the study's prespecified outcomes have been reported or one or more primary outcomes are reported using measurements, analysis methods or subsets of data that were not prespecified; or one or more reported primary outcomes were not prespecified, unless clear justification for their reporting is provided, such as an unexpected adverse effect, or one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta‐analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study </p> <p>*Unclear: there is insufficient information to permit judgement of "Low risk" or "High risk" </p> <p>For each domain, two authors independently made the judgment of risk of bias in accordance with the following classification: Low risk of bias; High risk of bias; Unclear. </p> </section> <section id="CD001990-sec-0058"> <h4 class="title">Measures of treatment effect</h4> <p>Treatment effect measures had to be computed by means of relative risks (dichotomous data), hazard ratios, and standardised mean differences (continuous data). A narrative description of results was reported in the first‐line chemotherapy studies. In the second‐line chemotherapy studies it was possible to obtain an overall effect measure of two studies. The third study was reported in a narrative. The statistical analysis was done in line with the recommendations of The Cochrane Collaboration using RevMan 5.2. We pooled the study specific hazard ratio estimates and their standard errors to obtain an overall hazard ratio and its 95% confident interval. We used as the method of meta‐analysis the inverse variance with the random‐effects model of Der Simonian and Laird to calculate the effect size, because of the clinical and methodological heterogeneity of the studies. Heterogeneity in the effect estimates was quantified with the I<sup>2</sup> statistic, which indicates the proportion of the total variation in the estimates that is caused by variation between studies not by chance. We considered I<sup>2</sup> &lt; 25% as representing low heterogeneity and I<sup>2</sup> &gt; 75% as representing high heterogeneity. </p> <p>Missing data were dealt with by analysing only the available data and not if the trial authors did not provide them. The potential impact of missing data on the findings of the review were addressed in the discussion section. </p> </section> <section id="CD001990-sec-0059"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis in all the included trials was the patient.</p> </section> <section id="CD001990-sec-0060"> <h4 class="title">Dealing with missing data</h4> <p>To obtain data not available in the included studies, we attempted to contact the principal study investigators. </p> </section> <section id="CD001990-sec-0061"> <h4 class="title">Assessment of heterogeneity</h4> <p>In terms of clinical heterogeneity, we explored any kind of variability among studies. We assessed baseline group imbalance as well as other sources of clinical heterogeneity such as different diagnostic methods among the studies and groups, adverse effects, differences in dose of drug, length of follow‐up, and characteristics of participants. We explored heterogeneity in the meta‐analysis by comparing studies in terms of methodological factors such as concealment of allocation, the definition and measurement of outcomes, as well as in relation to clinical heterogeneity. </p> </section> <section id="CD001990-sec-0062"> <h4 class="title">Assessment of reporting biases</h4> <p>We took into account the following:</p> <p> <ul id="CD001990-list-0006"> <li> <p>publication bias, by contacting pharmaceutical companies for non‐published studies; duplicate publication; reporting of outcomes; no language restrictions for inclusion of trials; </p> </li> <li> <p>the influence of external funding and commercial interests;</p> </li> <li> <p>a search of multiple database sources, and consulting trials registries.</p> </li> </ul> </p> <p>Since very few studies were included, we did not explore the use of funnel plots.</p> </section> <section id="CD001990-sec-0063"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analyses were to be done for subsets of participants (gender, age) or for subsets of studies (low risk versus high risk of bias) as a means of evaluating heterogeneous results, if there were a substantial number of studies. </p> <p>As it was not possible to perform any subgroup analysis in this review, we reported either differences in study and patient characteristics, the way in which outcomes were defined or measured, protocol requirements, the length of follow‐up, or differential losses to follow‐up. That is, clinical or methodology heterogeneity. </p> </section> <section id="CD001990-sec-0064"> <h4 class="title">Sensitivity analysis</h4> <p>No sensitivity analysis was performed due to the small number of included studies. References to better quality studies were described. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001990-sec-0065" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001990-sec-0065"></div> <section id="CD001990-sec-0066"> <h3 class="title">Description of studies</h3> <section id="CD001990-sec-0067"> <h4 class="title">Results of the search</h4> <p>From the literature search we obtained 16,282 references, 12,328 from MEDLINE and CENTRAL and 3954 from EMBASE, after excluding duplicates. We identified 50 potentially eligible trials in the first update and another five in the second update (<a href="#CD001990-fig-0001">Figure 1</a>). Only five trials compared first or second‐line chemotherapy versus placebo or BSC: two compared first‐line chemotherapy versus supportive care or no active anticancer treatment (<a href="./references#CD001990-bbs2-0002" title="KokronO , TitscherR , MickscheM , CerniC , WrbaH . Clinical experiences with Holoxan in small ceIl carcinoma of the bronchus (authors transl). Osterreichische Kneipp Magazin1977;15:103‐8. ">Kokron 1977b</a>; <a href="./references#CD001990-bbs2-0003" title="KokronO , MicksheM , TitscherR , WrbaH . Ifosfamide versus ifosfamide + CCNU in the treatment of inoperable small celI lung cancer. A clinical study. Onkologie1982;56:56‐9. ">Kokron 1982</a>) and the other three compared second‐line chemotherapy at relapse or progression versus symptomatic treatment or BSC (<a href="./references#CD001990-bbs2-0001" title="CiuleanuT , SamarzjiaM , DemidchikY , BeliakouskiV , RancicM , BentsionDL , et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first‐line platinum‐based chemotherapy. Journal of Clinical Oncology (ASCO)2010;28(15 Suppl):7002. ">Ciuleanu 2010</a>; <a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a>; <a href="./references#CD001990-bbs2-0006" title="SpiroSG , SouhamiRL , GeddesDM , AshCM , QuinnH , HarperPG , et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer1989;59:578‐83. ">Spiro 1989</a>). In the search for the second update we found the Ciuleanu trial; two reports of quality of life in relation to <a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a>, one was a repetition of the same results of the study so it was excluded (see <a href="./references#CD001990-sec-0112" title="">Characteristics of excluded studies</a>), the other study (<a href="./references#CD001990-bbs2-0005" title="O'BrianME , DuhMS , ChenL , AntrasL , NearyM , GrallaRJ . An analysis of disease control: is major response associated with greater symptomatic benefits than stable disease in small cell lung cancer (SCLC)? Results from the randomised Oral Topotecan (OT) vs. Best Supportive Care (BSC) trial: P1‐224. Journal of Thoracic Oncology2007;2(8):S827. ">O'Brien 2007a</a>) offered complementary information about quality of life and was included; another study, which was a retrospective report, was excluded. The Ciuleanu study was in abstract form and we consulted the Poniard website of the study (www.prnewswire.com/news‐releases/poniard‐announces‐final‐data‐from‐phase‐3‐spear‐trial‐of‐picoplatin‐in‐small‐cell‐lung‐cancer‐95693244.html) for more complete information. We did not identify any studies of first‐line chemotherapy versus BSC after 2003, when the original review took place. We received no response from the pharmaceutical companies that we contacted for information about any possible non‐published studies except for Lilly and Astra Zeneca saying that they had no unpublished studies corresponding to our review. Contact was established with the principal author of the Ciuleanu 2010 study but he was not able to reply to our questions due to the fact that the study's data are the property of Poniard Pharmaceuticals; the company did not reply to his questions either. </p> <div class="figure" id="CD001990-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD001990-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001990.pub3/media/CDSR/CD001990/image_n/nCD001990-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD001990-sec-0068"> <h4 class="title">Included studies</h4> <p>This review focused on the two trials by Kokron (<a href="./references#CD001990-bbs2-0002" title="KokronO , TitscherR , MickscheM , CerniC , WrbaH . Clinical experiences with Holoxan in small ceIl carcinoma of the bronchus (authors transl). Osterreichische Kneipp Magazin1977;15:103‐8. ">Kokron 1977b</a>; <a href="./references#CD001990-bbs2-0003" title="KokronO , MicksheM , TitscherR , WrbaH . Ifosfamide versus ifosfamide + CCNU in the treatment of inoperable small celI lung cancer. A clinical study. Onkologie1982;56:56‐9. ">Kokron 1982</a>), identified in the original review of 2003, and on the three trials by Spiro, O’Brien, and Ciuleanu (<a href="./references#CD001990-bbs2-0001" title="CiuleanuT , SamarzjiaM , DemidchikY , BeliakouskiV , RancicM , BentsionDL , et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first‐line platinum‐based chemotherapy. Journal of Clinical Oncology (ASCO)2010;28(15 Suppl):7002. ">Ciuleanu 2010</a>; <a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a>; <a href="./references#CD001990-bbs2-0006" title="SpiroSG , SouhamiRL , GeddesDM , AshCM , QuinnH , HarperPG , et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer1989;59:578‐83. ">Spiro 1989</a>), the only ones that fulfilled the inclusion criteria. </p> <section id="CD001990-sec-0069"> <h5 class="title">First‐line chemotherapy versus best supportive care (BSC)</h5> <p>Two studies included a total of 88 patients. See <a href="#CD001990-tbl-0003">Table 1</a> for further details. </p> <div class="table" id="CD001990-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">First‐line chemotherapy versus best supportive care (BSC)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group A</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group B</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group C</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kokron 1977b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supportive care: mainly antibiotics and analgesics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ifosfamide monotherapy: 1500 mg/m<sup>2</sup> ifosfamide </p> <p>as short infusion iv. on day 1, followed by ifosfamide</p> <p>1000 mg/m<sup>2</sup> iv.on days 2 and 3. Repetition of ifosfamide </p> <p>1000 mg/m<sup>2</sup> iv on days 8, 9, 10 and 15,16,17. </p> <p>Continuation of the therapy after six weeks with three day therapy (1000 mg/m<sup>2</sup> daily each). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kokron 1982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No active anticancer treatment: infusion of Ringers solution 1000 ml + 1 gr vitamin C iv three times a week during an in‐patient stay. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ifosfamide monotherapy: same schedule as the first study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ifosfamide + CCNU (chloroethyl‐cyclohexyl‐nitrosourea):</p> <p>ifosfamide therapy as described under Group B,</p> <p>in addition to CCNU 60 mg/m<sup>2</sup> on day 1 with repetition after six weeks. </p> </td> </tr> </tbody> </table> </div> <p><a href="./references#CD001990-bbs2-0002" title="KokronO , TitscherR , MickscheM , CerniC , WrbaH . Clinical experiences with Holoxan in small ceIl carcinoma of the bronchus (authors transl). Osterreichische Kneipp Magazin1977;15:103‐8. ">Kokron 1977b</a> included 34 patients (33 evaluable) selected from 1972 to 1974 with the objective of comparing ifosfamide with supportive care. </p> <p><a href="./references#CD001990-bbs2-0003" title="KokronO , MicksheM , TitscherR , WrbaH . Ifosfamide versus ifosfamide + CCNU in the treatment of inoperable small celI lung cancer. A clinical study. Onkologie1982;56:56‐9. ">Kokron 1982</a> was published in 1982 and included 54 eligible patients (41 of them with extensive disease, 32 evaluable) selected between 1975 and 1979. The objective of this study was to compare ifosfamide versus ifosfamide plus chloroethyl‐cyclohexyl‐nitrosourea (CCNU) versus no active anticancer treatment. Both studies were carried out at the City Hospital Lainz, Vienna. </p> <p>The inclusion criteria for the trials were: male patients; age under 70 years; inoperable small cell carcinoma of the bronchus with histological or cytological verification of tumour, or both; no previous tumour therapy; no large total tumour mass; no detected brain metastasis at the start of therapy; no chronic disease (cardiac, hepatocirrhosis, renal insufficiency, insulin dependent diabetes, or impediment in the region of the urinary tract) and good general condition (able to work) (see <a href="./references#CD001990-sec-0111" title="">Characteristics of included studies</a>, <a href="#CD001990-fig-0002">Figure 2</a>, <a href="#CD001990-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD001990-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001990-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001990.pub3/media/CDSR/CD001990/image_n/nCD001990-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD001990-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001990-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001990.pub3/media/CDSR/CD001990/image_n/nCD001990-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> </section> <section id="CD001990-sec-0070"> <h5 class="title">Second‐line chemotherapy at relapse versus best supportive care (BSC)</h5> <p>Three studies included a total of 932 patients. See <a href="#CD001990-tbl-0004">Table 2</a> for more information. </p> <div class="table" id="CD001990-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Second‐line chemotherapy at relapse versus best supportive care (BSC)</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group A</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group B</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spiro 1989*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Symptomatic treatment including palliative irradiation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methotrexate 50 mg/m<sup>2</sup> iv plus doxorubicin 50 mg/m<sup>2</sup> iv, repeated every </p> <p>three weeks with a maximum of nine courses</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>O'Brien 2006**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BSC<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Topotecan in capsules containing the equivalent to 0.25 mg, doses</p> <p>2.3 mg/m<sup>2</sup> on days 1 to 5 every 21 days, at least four cycles + BSC. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ciuleanu 2010***</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BSC<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Picoplatin 150 mg/m<sup>2</sup>, every 3 weeks median cycles 3 </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Patients with disease progression. First‐line chemotherapy treatment consisted of either four or eight cycles of cyclophosphamide 1 g/m<sup>2</sup> iv; vincristine 1.4 mg/m<sup>2</sup> iv; on day 1, and etoposide capsules 100 mg orally eight hourly on days 1 to 3, every 21 days </p> <p>**Patients with relapse and who were unsuitable for further intravenous chemotherapy</p> <p>***Patients with refractory disease or progression within six months after first‐line platinum‐based chemotherapy </p> <p>a = Best Supportive Care</p> </div> </div> <p><a href="./references#CD001990-bbs2-0006" title="SpiroSG , SouhamiRL , GeddesDM , AshCM , QuinnH , HarperPG , et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer1989;59:578‐83. ">Spiro 1989</a> included 616 patients (610 evaluable), 414 of them with advanced SCLC, recruited from 1982 to 1985 at various institutions in the United Kingdom. Second‐line chemotherapy or symptomatic treatment was administered to 390 patients in progression (170 evaluable in active treatment). </p> <p><a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a> included 141 patients (141 evaluable) recruited from 2000 to 2004 at 40 centres in Europe, Canada, and Russia. </p> <p><a href="./references#CD001990-bbs2-0001" title="CiuleanuT , SamarzjiaM , DemidchikY , BeliakouskiV , RancicM , BentsionDL , et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first‐line platinum‐based chemotherapy. Journal of Clinical Oncology (ASCO)2010;28(15 Suppl):7002. ">Ciuleanu 2010</a> included 401 patients (321 evaluable) with refractory disease or SCLC in progression within six months of first‐line chemotherapy, recruited from international multi‐centre sites. </p> <p>The inclusion criteria for the trials were: both sexes; age under 75 years (<a href="./references#CD001990-bbs2-0006" title="SpiroSG , SouhamiRL , GeddesDM , AshCM , QuinnH , HarperPG , et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer1989;59:578‐83. ">Spiro 1989</a>) or ≥ 18 years (<a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a>); median age 58 years (<a href="./references#CD001990-bbs2-0001" title="CiuleanuT , SamarzjiaM , DemidchikY , BeliakouskiV , RancicM , BentsionDL , et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first‐line platinum‐based chemotherapy. Journal of Clinical Oncology (ASCO)2010;28(15 Suppl):7002. ">Ciuleanu 2010</a>); SCLC diagnosed by histology or by cytology; previous chemotherapy; no symptomatic brain metastases (<a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a>); no severe co‐morbidities; no previous treatment with topotecan (<a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a>); any performance status (<a href="./references#CD001990-bbs2-0006" title="SpiroSG , SouhamiRL , GeddesDM , AshCM , QuinnH , HarperPG , et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer1989;59:578‐83. ">Spiro 1989</a>) or between 0 and 2 (<a href="./references#CD001990-bbs2-0001" title="CiuleanuT , SamarzjiaM , DemidchikY , BeliakouskiV , RancicM , BentsionDL , et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first‐line platinum‐based chemotherapy. Journal of Clinical Oncology (ASCO)2010;28(15 Suppl):7002. ">Ciuleanu 2010</a>; <a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a>). </p> <p>The primary endpoint in the five trials was overall survival. Secondary endpoints were response rate, quality of life, and safety. </p> <p>Supplementary data from the Kokron studies were supplied by the author. We were unable to establish contact with the rest of authors. </p> </section> </section> <section id="CD001990-sec-0071"> <h4 class="title">Excluded studies</h4> <p>A total of 48 studies were excluded. These studies did not include a comparison of a chemotherapeutic agent with placebo or BSC, were phase II trials without a control group, or they compared second‐line chemotherapy in a complete or partial response with observation (see <a href="./references#CD001990-sec-0112" title="">Characteristics of excluded studies</a>). </p> </section> </section> <section id="CD001990-sec-0072"> <h3 class="title">Risk of bias in included studies</h3> <p>See the 'Risk of bias' tables in <a href="./references#CD001990-sec-0111" title="">Characteristics of included studies</a>. </p> <section id="CD001990-sec-0073"> <h4 class="title">Allocation</h4> <p>The allocation strategy was considered unclear for the five trials (<a href="./references#CD001990-bbs2-0001" title="CiuleanuT , SamarzjiaM , DemidchikY , BeliakouskiV , RancicM , BentsionDL , et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first‐line platinum‐based chemotherapy. Journal of Clinical Oncology (ASCO)2010;28(15 Suppl):7002. ">Ciuleanu 2010</a>; <a href="./references#CD001990-bbs2-0002" title="KokronO , TitscherR , MickscheM , CerniC , WrbaH . Clinical experiences with Holoxan in small ceIl carcinoma of the bronchus (authors transl). Osterreichische Kneipp Magazin1977;15:103‐8. ">Kokron 1977b</a>; <a href="./references#CD001990-bbs2-0003" title="KokronO , MicksheM , TitscherR , WrbaH . Ifosfamide versus ifosfamide + CCNU in the treatment of inoperable small celI lung cancer. A clinical study. Onkologie1982;56:56‐9. ">Kokron 1982</a>; <a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a>; <a href="./references#CD001990-bbs2-0005" title="O'BrianME , DuhMS , ChenL , AntrasL , NearyM , GrallaRJ . An analysis of disease control: is major response associated with greater symptomatic benefits than stable disease in small cell lung cancer (SCLC)? Results from the randomised Oral Topotecan (OT) vs. Best Supportive Care (BSC) trial: P1‐224. Journal of Thoracic Oncology2007;2(8):S827. ">O'Brien 2007a</a>; <a href="./references#CD001990-bbs2-0006" title="SpiroSG , SouhamiRL , GeddesDM , AshCM , QuinnH , HarperPG , et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer1989;59:578‐83. ">Spiro 1989</a>), while allocation concealment was judged adequate for one trial (<a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a>; <a href="./references#CD001990-bbs2-0005" title="O'BrianME , DuhMS , ChenL , AntrasL , NearyM , GrallaRJ . An analysis of disease control: is major response associated with greater symptomatic benefits than stable disease in small cell lung cancer (SCLC)? Results from the randomised Oral Topotecan (OT) vs. Best Supportive Care (BSC) trial: P1‐224. Journal of Thoracic Oncology2007;2(8):S827. ">O'Brien 2007a</a>) and unclear for the other four trials (<a href="./references#CD001990-bbs2-0001" title="CiuleanuT , SamarzjiaM , DemidchikY , BeliakouskiV , RancicM , BentsionDL , et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first‐line platinum‐based chemotherapy. Journal of Clinical Oncology (ASCO)2010;28(15 Suppl):7002. ">Ciuleanu 2010</a>; <a href="./references#CD001990-bbs2-0002" title="KokronO , TitscherR , MickscheM , CerniC , WrbaH . Clinical experiences with Holoxan in small ceIl carcinoma of the bronchus (authors transl). Osterreichische Kneipp Magazin1977;15:103‐8. ">Kokron 1977b</a>; <a href="./references#CD001990-bbs2-0003" title="KokronO , MicksheM , TitscherR , WrbaH . Ifosfamide versus ifosfamide + CCNU in the treatment of inoperable small celI lung cancer. A clinical study. Onkologie1982;56:56‐9. ">Kokron 1982</a>; <a href="./references#CD001990-bbs2-0006" title="SpiroSG , SouhamiRL , GeddesDM , AshCM , QuinnH , HarperPG , et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer1989;59:578‐83. ">Spiro 1989</a>). Although we actively contacted the authors requesting information about their trials, we received no replies. </p> </section> <section id="CD001990-sec-0074"> <h4 class="title">Blinding</h4> <p>Blinding was not used in four of the five trials but the main outcome of survival is not likely to be influenced by lack of blinding. </p> </section> <section id="CD001990-sec-0075"> <h4 class="title">Incomplete outcome data</h4> <p>Losses to follow‐up and their reasons were reported in only one trial (<a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a>; <a href="./references#CD001990-bbs2-0005" title="O'BrianME , DuhMS , ChenL , AntrasL , NearyM , GrallaRJ . An analysis of disease control: is major response associated with greater symptomatic benefits than stable disease in small cell lung cancer (SCLC)? Results from the randomised Oral Topotecan (OT) vs. Best Supportive Care (BSC) trial: P1‐224. Journal of Thoracic Oncology2007;2(8):S827. ">O'Brien 2007a</a>). Attrition data seemed to be different between groups. </p> </section> <section id="CD001990-sec-0076"> <h4 class="title">Selective reporting</h4> <p>Relevant outcomes for this review were reported in only one trial (<a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a>; <a href="./references#CD001990-bbs2-0005" title="O'BrianME , DuhMS , ChenL , AntrasL , NearyM , GrallaRJ . An analysis of disease control: is major response associated with greater symptomatic benefits than stable disease in small cell lung cancer (SCLC)? Results from the randomised Oral Topotecan (OT) vs. Best Supportive Care (BSC) trial: P1‐224. Journal of Thoracic Oncology2007;2(8):S827. ">O'Brien 2007a</a>). </p> </section> <section id="CD001990-sec-0077"> <h4 class="title">Other potential sources of bias</h4> <p>Four studies (<a href="./references#CD001990-bbs2-0001" title="CiuleanuT , SamarzjiaM , DemidchikY , BeliakouskiV , RancicM , BentsionDL , et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first‐line platinum‐based chemotherapy. Journal of Clinical Oncology (ASCO)2010;28(15 Suppl):7002. ">Ciuleanu 2010</a>; <a href="./references#CD001990-bbs2-0002" title="KokronO , TitscherR , MickscheM , CerniC , WrbaH . Clinical experiences with Holoxan in small ceIl carcinoma of the bronchus (authors transl). Osterreichische Kneipp Magazin1977;15:103‐8. ">Kokron 1977b</a>; <a href="./references#CD001990-bbs2-0003" title="KokronO , MicksheM , TitscherR , WrbaH . Ifosfamide versus ifosfamide + CCNU in the treatment of inoperable small celI lung cancer. A clinical study. Onkologie1982;56:56‐9. ">Kokron 1982</a>; <a href="./references#CD001990-bbs2-0006" title="SpiroSG , SouhamiRL , GeddesDM , AshCM , QuinnH , HarperPG , et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer1989;59:578‐83. ">Spiro 1989</a>) were considered to be affected by other sources of bias. </p> </section> </section> <section id="CD001990-sec-0078"> <h3 class="title" id="CD001990-sec-0078">Effects of interventions</h3> <p>See: <a href="./full#CD001990-tbl-0001"><b>Summary of findings for the main comparison</b> First‐line chemotherapy compared with BSC for extensive SCLC</a>; <a href="./full#CD001990-tbl-0002"><b>Summary of findings 2</b> Second‐line chemotherapy at relapse or progression in extensive SCLC</a> </p> <section id="CD001990-sec-0079"> <h4 class="title">A) First‐line chemotherapy versus best supportive care (BSC)</h4> <p>The results were based on a total of 65 assessed patients with advanced disease who were included in two studies (<a href="./references#CD001990-bbs2-0002" title="KokronO , TitscherR , MickscheM , CerniC , WrbaH . Clinical experiences with Holoxan in small ceIl carcinoma of the bronchus (authors transl). Osterreichische Kneipp Magazin1977;15:103‐8. ">Kokron 1977b</a>; <a href="./references#CD001990-bbs2-0003" title="KokronO , MicksheM , TitscherR , WrbaH . Ifosfamide versus ifosfamide + CCNU in the treatment of inoperable small celI lung cancer. A clinical study. Onkologie1982;56:56‐9. ">Kokron 1982</a>). Information about the baseline data of the patients in the two arms and a calculation of sample size were not found in the Kokron reports. The published studies of Kokron did not provide sufficient details about the analyses performed, although survival curves were used to compare survival between groups in both studies. Information that was later provided by the author referred to ANOVA to compare the three groups in the second study (<a href="./references#CD001990-bbs2-0003" title="KokronO , MicksheM , TitscherR , WrbaH . Ifosfamide versus ifosfamide + CCNU in the treatment of inoperable small celI lung cancer. A clinical study. Onkologie1982;56:56‐9. ">Kokron 1982</a>). </p> <p>Because it was not possible to obtain data suitable for a combined analysis, the results were described separately for each study according to the data provided by the author. Results for each study are presented in <a href="#CD001990-tbl-0005">Table 3</a>. </p> <div class="table" id="CD001990-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Results of the studies included in the review (first‐line chemotherapy versus best supportive care (BSC)</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> <p><b>ID</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Objective</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Survival</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tumour response</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Toxicity</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Kokron 1977b</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To compare supportive care vs Ifosfamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MST<sup>1:</sup> supportive care group = 93 days vs 172 Ifosfamide group (range:11 to 544 vs 1 to 1096) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PR<sup>2</sup> = 0%  supportive care group vs 47% Ifosfamide group </p> <p>CR<sup>3</sup>= 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haematological: 0%  supportive care group vs  94.1% Ifosfamide group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Kokron 1982</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To compare no active anticancer treatment vs ifosfamide vs Ifosfamide + CCNU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MST: in extensive disease: no active anticancer treatment = 56 days vs 134 Ifosfamide vs 122 Ifosfamide + CCNU. Grouped data: no active anticancer treatment, median = 161.5 (MST = 208.4), Ifosfamide, median = 341 (MST = 348.5), Ifosfamide + CCNU, median = 252 (MST = 322.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grouped data (extensive and limited disease): CR = 1.9% Ifosfamide; PR = 16.9 Ifosfamide, and 13.2% Ifosfamide + CCNU </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grouped data: leucopenia:0% no active anticancer treatment; 15% Ifosfamide; 15.8% Ifosfamide + CCNU. Vomiting and hair loss: 0% no active anticancer treatment, 70% Ifosfamide; 68.4% Ifosfamide + CCNU. Other: 0% no active anticancer treatment; 55% Ifosfamide; 52.6% Ifosfamide + CCNU </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>MST = mean survival time; PR = partial response; CR = complete response; CCNU = cyclohexylnitrosourea</p> </div> </div> <section id="CD001990-sec-0080"> <h5 class="title">Survival</h5> <p> <ul id="CD001990-list-0007"> <li> <p><i>Mean survival</i> </p> </li> </ul> </p> <p> In <a href="./references#CD001990-bbs2-0002" title="KokronO , TitscherR , MickscheM , CerniC , WrbaH . Clinical experiences with Holoxan in small ceIl carcinoma of the bronchus (authors transl). Osterreichische Kneipp Magazin1977;15:103‐8. ">Kokron 1977b</a>, treatment with ifosfamide gave a mean survival time that was 79 days longer than in the supportive care group. Available data did not allow calculation of the confidence interval. </p> <p>In <a href="./references#CD001990-bbs2-0003" title="KokronO , MicksheM , TitscherR , WrbaH . Ifosfamide versus ifosfamide + CCNU in the treatment of inoperable small celI lung cancer. A clinical study. Onkologie1982;56:56‐9. ">Kokron 1982</a>, the data for all patients (limited and extensive disease) showed a significant difference (P = 0.01) in the mean survival time between the no active anticancer treatment and the ifosfamide groups and between the no active anticancer treatment and the ifosfamide + CCNU groups. No significant differences were found between the ifosfamide and ifosfamide + CCNU groups. For patients with extensive disease, where only the mean survival time was reported by the author, the mean survival time was 78 days longer (P = 0.01) for the ifosfamide group and 66 days longer (P = 0.01) for the ifosfamide + CCNU group in comparison with the no active anticancer treatment group. In addition, in the ifosfamide group the mean survival time was 12 days longer (P = 0.05) than in the group receiving ifosfamide + CCNU. The quality of the evidence was very low for this outcome. (See <a href="./full#CD001990-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD001990-sec-0081"> <h5 class="title">Tumour response</h5> <p>No patients in <a href="./references#CD001990-bbs2-0002" title="KokronO , TitscherR , MickscheM , CerniC , WrbaH . Clinical experiences with Holoxan in small ceIl carcinoma of the bronchus (authors transl). Osterreichische Kneipp Magazin1977;15:103‐8. ">Kokron 1977b</a> showed a complete response. However, eight patients (47%) in the ifosfamide group showed a partial response at 5.6 months versus no patients in the control group. In <a href="./references#CD001990-bbs2-0003" title="KokronO , MicksheM , TitscherR , WrbaH . Ifosfamide versus ifosfamide + CCNU in the treatment of inoperable small celI lung cancer. A clinical study. Onkologie1982;56:56‐9. ">Kokron 1982</a> only one patient in the ifosfamide treatment group had a complete tumour response. Nine patients in the ifosfamide group and seven in the ifosfamide + CCNU group showed a partial tumour response. These data referred to all patients (limited and extensive disease) as the author did not report data specifically for patients with extensive disease. </p> </section> <section id="CD001990-sec-0082"> <h5 class="title">Toxicity</h5> <p>In <a href="./references#CD001990-bbs2-0002" title="KokronO , TitscherR , MickscheM , CerniC , WrbaH . Clinical experiences with Holoxan in small ceIl carcinoma of the bronchus (authors transl). Osterreichische Kneipp Magazin1977;15:103‐8. ">Kokron 1977b</a> six patients (94.1%) treated with ifosfamide had haematological toxicity (its type was not reported) compared with none in the supportive care group. In <a href="./references#CD001990-bbs2-0003" title="KokronO , MicksheM , TitscherR , WrbaH . Ifosfamide versus ifosfamide + CCNU in the treatment of inoperable small celI lung cancer. A clinical study. Onkologie1982;56:56‐9. ">Kokron 1982</a>, data on toxicity referred to all patients (limited and extensive disease), where no cases of toxicity were recorded for the no active anticancer treatment group (very low‐quality evidence). </p> </section> <section id="CD001990-sec-0083"> <h5 class="title">Quality of life</h5> <p>No validated instruments were used to assess quality of life in the Kokron studies (<a href="./references#CD001990-bbs2-0002" title="KokronO , TitscherR , MickscheM , CerniC , WrbaH . Clinical experiences with Holoxan in small ceIl carcinoma of the bronchus (authors transl). Osterreichische Kneipp Magazin1977;15:103‐8. ">Kokron 1977b</a>; <a href="./references#CD001990-bbs2-0003" title="KokronO , MicksheM , TitscherR , WrbaH . Ifosfamide versus ifosfamide + CCNU in the treatment of inoperable small celI lung cancer. A clinical study. Onkologie1982;56:56‐9. ">Kokron 1982</a>). Patients’ levels of activity were assessed (<a href="./references#CD001990-bbs2-0003" title="KokronO , MicksheM , TitscherR , WrbaH . Ifosfamide versus ifosfamide + CCNU in the treatment of inoperable small celI lung cancer. A clinical study. Onkologie1982;56:56‐9. ">Kokron 1982</a>) using a simple scale: 0: no symptoms, 1: subjective symptoms only, 2: objective signs of illness but able to work, 3: needing care, 4: bedridden, 5: confused and disorientated. No information or reference was given concerning its validation. Data based on this scale were reported only for the beginning of treatment (for all patients together, limited and extensive disease) when 34 had an activity level of 1 and 18 were level 2. The data also showed that 61% of patients in the first group, 80% in the second, and 53% in the third presented a subjective feeling of disease with a score of 1 on the scale. No specific information was mentioned for patients with extensive disease and no measurement of this scale was reported at the end of the study. </p> </section> </section> <section id="CD001990-sec-0084"> <h4 class="title">B) Second‐line chemotherapy versus best supportive care (BSC) at relapse or progression</h4> <p>The results of this comparison were based on a total of 932 patients with advanced disease who were included in three studies (<a href="./references#CD001990-bbs2-0001" title="CiuleanuT , SamarzjiaM , DemidchikY , BeliakouskiV , RancicM , BentsionDL , et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first‐line platinum‐based chemotherapy. Journal of Clinical Oncology (ASCO)2010;28(15 Suppl):7002. ">Ciuleanu 2010</a>; <a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a>; <a href="./references#CD001990-bbs2-0006" title="SpiroSG , SouhamiRL , GeddesDM , AshCM , QuinnH , HarperPG , et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer1989;59:578‐83. ">Spiro 1989</a>). All patients in progression or relapse were considered as having extensive disease in this review. Information about the baseline data of patients in the two arms and a calculation of sample size were described in <a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a>. </p> <p>In <a href="./references#CD001990-bbs2-0006" title="SpiroSG , SouhamiRL , GeddesDM , AshCM , QuinnH , HarperPG , et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer1989;59:578‐83. ">Spiro 1989</a>, randomisation took place at diagnosis not relapse and patient characteristics were described at presentation with either limited or extensive disease. O'Brien provided baseline characteristics of the patients but Ciuleanu did not. </p> <p>Patients in <a href="./references#CD001990-bbs2-0006" title="SpiroSG , SouhamiRL , GeddesDM , AshCM , QuinnH , HarperPG , et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer1989;59:578‐83. ">Spiro 1989</a> were allocated to one of two groups: 192 (59 women) to the methotrexate‐doxorubicin group and 198 (63 women) to the symptomatic treatment group. Patients in <a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a> were allocated to one of two groups: 71 (19 women) to the topotecan group and 70 (19 women) to the BSC group. Patients in the <a href="./references#CD001990-bbs2-0001" title="CiuleanuT , SamarzjiaM , DemidchikY , BeliakouskiV , RancicM , BentsionDL , et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first‐line platinum‐based chemotherapy. Journal of Clinical Oncology (ASCO)2010;28(15 Suppl):7002. ">Ciuleanu 2010</a> study were allocated to one of two groups: 268 picoplatin, 133 BSC. Results for each study are presented in <a href="#CD001990-tbl-0006">Table 4</a> and in the 'Data analysis' section. </p> <div class="table" id="CD001990-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Results of the studies included in the review (second‐line chemotherapy versus best supportive care (BSC)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> <p><b>ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Objective</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Survival</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tumour response</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Toxicity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Spiro 1989</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To assess the effects of duration of chemotherapy on survival, <i>and</i> at relapse, the effects of further chemotherapy compared with symptomatic treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MST<sup>1</sup>: symptomatic = 77 to 84 days vs 140 to 105 days methotrexate‐doxorubicin group (<i>in previous chemotherapy: 4 cycles‐8 cycles, vs 4 cycles‐8 cycles)</i> Only significant 77 vs 140 days (P &lt; 0.001) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PR<sup>2</sup> or CR<sup>3</sup> in methotrexate‐doxorubicin group = 22.3% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not provided for second‐line chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>O'Brien 2006</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To define risk and benefit of second‐line chemotherapy at relapse vs BSC in patients unsuitable for standard intravenous chemotherapy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MST: in BSC 97.3 days (95% CI, 77.7 to 130.2) vs  181.3 days (95% CI, 128.1 to 221.2) in Topotecan group (log‐rank P = 0.01) </p> <p><i>Subgroup analysis</i> </p> <p>a) treatment‐free interval &lt;=60 days of first‐line chemotherapy: topotecan 163.1 (95% CI 74.9 to 216.3) vs BSC 92.4 (95% CI 49 to 147) </p> <p>b) performance status 2: topotecan 146.3 (93.8 to 188.3) vs BSC 53.9 (37.1 to 91.7)</p> <p>c) female: HR 0.38 (95% CI 0.18 to 0.76)</p> <p>d) liver metastasis: HR 0.58 (95% CI 0.38 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PR  in the topotecan group = 7% (95% CI, 2.33 to 15.67)</p> <p>CR 0%</p> <p>In treatment‐free interval &lt;=60 days: PR 18% (5.2 to 40.3) vs 2% 80.05 to 10.9) in treatment‐free interval &gt;60 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topotecan group: <i>Haematological</i>: neutropenia ¾, 61%; thrombocytopenia ¾, 38%, anaemia ¾, 25%. Nonsepsis infection&gt;= grade 2, 14%, vs 12% in BSC. Sepsis 4% in topotecan vs 1% in BSC. </p> <p><i>Non‐haematologica</i>l 3/4 in topotecan vs BSC: dyspnoea 3% vs 9%; fatigue 4% vs 4%. </p> <p>Toxic deaths in topotecan: 6%</p> <p>all‐cause mortality within 30 days: 7% topotecan vs 13% BSC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Difference in rate of deterioration per 3‐month intervals in EQ‐5D was 0.15 (95% CI 0.05 to 0.25) </p> <p>In PSA questionnaire:</p> <p>shortness of breath RR 2.18 (1.09 to 4.38)</p> <p>interference with sleep 2.16 (1.15 to 4.06)</p> <p>fatigue 2.29 (1.25 to 4.19)</p> <p>All in favour of topotecan</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ciuleanu 2010</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>To assess survival of patients treated with second‐line chemotherapy who were refractory or who progressed within six months of first‐line platinum‐based chemotherapy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MST: in BSC 138 days (95% CI 112 to 168)</p> <p>in picoplatin 144 days (95% CI 133 to 175)</p> <p>HR: 0.817 95% CI 0.65 to 1.03 (P=0.00895)</p> <p>Time to progression:79 days picoplatin, 47 days BSC</p> <p>HR: 0.610 (P=0.0002)</p> <p>Median progression‐free survival: 63 days picoplatin, 46 days BSC</p> <p>HR: 0.783 (P=0.0281)</p> <p><i>Subgroup analysis</i> </p> <p>a) patients who did not receive chemotherapy post‐study (273: 194 picoplatin vs 79 BSC): picoplatin 128 days (95% CI 112 to 140), BSC 101 (77 to 140), HR 0.730 (P=0.0345) </p> <p>b) patients refractory or relapsed within 45 days of first‐line chemotherapy (294: 202 picoplatin vs 92 BSC): </p> <p>picoplatin 149, BSC 129,</p> <p>HR 0.717 (P=0.0173)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Picoplatin group: <i>Haematological</i>: 3/4 in &gt;10%: </p> <p>44% thrombocytopenia</p> <p>29% anaemia</p> <p>18% neutropenia</p> <p>&lt;1% febrile neutropenia</p> <p>No deaths to haematological toxicity, no bleeding</p> <p><i>Nonhaematological</i>: </p> <p>0.8% grade 3 neuropathy</p> <p>11% asthenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>MST = median survival time; PR = partial response CR = complete response; BSC = best support care; CI = confidence interval; EQ‐5D = EuroQol‐5‐Dimensions (mobility, self‐care, usual activities, pain and discomfort, anxiety and depression) with rating 1 (no problem) to 3 (extreme problem); PSA = Patient Self Assessment questionnaire, with rating 1 (not at all) to 4 (very much) </p> </div> </div> <section id="CD001990-sec-0085"> <h5 class="title">Survival</h5> <p> <ul id="CD001990-list-0008"> <li> <p><i>Median survival</i> </p> </li> </ul> </p> <p>In <a href="./references#CD001990-bbs2-0006" title="SpiroSG , SouhamiRL , GeddesDM , AshCM , QuinnH , HarperPG , et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer1989;59:578‐83. ">Spiro 1989</a>, survival data were provided in accordance with the first‐line chemotherapy group allocation: treatment with methotrexate‐doxorubicin at relapse gave a median survival time of 63 days longer than in the symptomatic treatment group (P &lt; 0.001) for patients allocated to receive four cycles of first‐line chemotherapy, and 21 days longer (P = 0.160) for patients allocated to receive eight cycles of first‐line chemotherapy. Confidence intervals were not reported. No survival comparisons between the symptomatic group versus the methotrexate group were provided. </p> <p>In <a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a>, treatment with topotecan at relapse gave a median survival time 84 days longer than in the BSC group (log‐rank P = 0.01). The hazard ratio for overall survival, adjusted for the stratification factors of sex, performance status 0/1 or 2, treatment‐free interval ≤ 60 days or &gt; 60 days, presence of liver metastases, was 0.61 (95% CI 0.43 to 0.87). </p> <p>In all subgroup analyses in the <a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a> study (treatment‐free interval ≤ 60 days after first‐line chemotherapy, performance status 2, female, liver metastasis) (see <a href="#CD001990-tbl-0006">Table 4</a>) the survival differences were maintained. </p> <p>In <a href="./references#CD001990-bbs2-0001" title="CiuleanuT , SamarzjiaM , DemidchikY , BeliakouskiV , RancicM , BentsionDL , et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first‐line platinum‐based chemotherapy. Journal of Clinical Oncology (ASCO)2010;28(15 Suppl):7002. ">Ciuleanu 2010</a>, treatment with picoplatin in refractory patients or for patients in progression gave a median survival time six days longer than in the BSC group (HR 0.82, 95% CI 0.65 to 1.03, P = 0.0895). The time to progression was significant longer (32 days) in the picoplatin group in comparison with the BSC group, and the median progression‐free survival was also significant longer (by 17 days) in the picoplatin group. Patients of both groups received second‐line chemotherapy post‐study, 27.6% in the picoplatin arm and 40.6% in the BSC arm (P = 0.012). </p> <p>In the first subgroup analysis of patients who did not receive second‐line chemotherapy post‐study in either arm (picoplatin or BSC), and in the second subgroup analysis of patients refractory or relapsed within 45 days of first‐line chemotherapy, a significant longer survival time was observed in the picoplatin group compared to the BSC group (see <a href="#CD001990-tbl-0006">Table 4</a>). </p> <p>The overall survival measured by means of the combined hazard ratio for topotecan plus picoplatin was 0.73 (95% CI 0.55 to 0.96, P = 0.03; low‐quality evidence), with medium heterogeneity (47%), favouring second‐line chemotherapy over BSC (see <a href="./full#CD001990-tbl-0002">summary of findings Table 2</a>, <a href="./references#CD001990-fig-0005" title="">Analysis 1.1</a>, <a href="#CD001990-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD001990-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Second‐line chemotherapy at relapse versus BSC, outcome: 1.1 Overall survival." data-id="CD001990-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001990.pub3/media/CDSR/CD001990/image_n/nCD001990-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Second‐line chemotherapy at relapse versus BSC, outcome: 1.1 Overall survival. </p> </div> </div> </div> <p> <ul id="CD001990-list-0009"> <li> <p><i>Survival at six months</i> </p> </li> </ul> </p> <p>Data were extracted from the survival curves and in accordance with the previous chemotherapy received: <a href="./references#CD001990-bbs2-0006" title="SpiroSG , SouhamiRL , GeddesDM , AshCM , QuinnH , HarperPG , et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer1989;59:578‐83. ">Spiro 1989</a> symptomatic group previously four cycles 20%; previously eight cycles 22%; in the methotrexate‐doxorubicin group previously four cycles 37%, previously eight cycles 32%. </p> <p>Six‐month survival rates were 26% in the BSC group and 49% in the topotecan group (<a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a>). No data were provided in the picoplatin study (<a href="./references#CD001990-bbs2-0001" title="CiuleanuT , SamarzjiaM , DemidchikY , BeliakouskiV , RancicM , BentsionDL , et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first‐line platinum‐based chemotherapy. Journal of Clinical Oncology (ASCO)2010;28(15 Suppl):7002. ">Ciuleanu 2010</a>). </p> <p> <ul id="CD001990-list-0010"> <li> <p><i>Survival at one year</i> </p> </li> </ul> </p> <p>Data were extracted from the survival curves and in accordance with previous chemotherapy received: <a href="./references#CD001990-bbs2-0006" title="SpiroSG , SouhamiRL , GeddesDM , AshCM , QuinnH , HarperPG , et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer1989;59:578‐83. ">Spiro 1989</a> symptomatic group previously four cycles 4%, previously eight cycles 2%; in the methotrexate‐doxorubicin group previously four cycles 6%, previously eight cycles 5%. </p> <p>One‐year survival rates (extrapolated from the survival graphs) were 13% in the BSC group and 19% in the topotecan group (<a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a>). No data were provided in the picoplatin study (<a href="./references#CD001990-bbs2-0001" title="CiuleanuT , SamarzjiaM , DemidchikY , BeliakouskiV , RancicM , BentsionDL , et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first‐line platinum‐based chemotherapy. Journal of Clinical Oncology (ASCO)2010;28(15 Suppl):7002. ">Ciuleanu 2010</a>). </p> <p> <ul id="CD001990-list-0011"> <li> <p><i>Survival at two years</i> </p> </li> </ul> </p> <p>Two‐year survival in patients with extensive disease at presentation, for both groups in <a href="./references#CD001990-bbs2-0006" title="SpiroSG , SouhamiRL , GeddesDM , AshCM , QuinnH , HarperPG , et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer1989;59:578‐83. ">Spiro 1989</a>, were shown according to first‐line chemotherapy allocation: 2% to 2.7% for the symptomatic group allocated to four and eight cycles respectively, and 1.1% to 1% for the methotrexate‐doxorubicin group allocated to four and eight cycles, respectively. In <a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a> the two‐year survival rates (extrapolated from the survival graphs) were 3% and 9% in the BSC and topotecan groups, respectively. No data were provided in the picoplatin study (<a href="./references#CD001990-bbs2-0001" title="CiuleanuT , SamarzjiaM , DemidchikY , BeliakouskiV , RancicM , BentsionDL , et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first‐line platinum‐based chemotherapy. Journal of Clinical Oncology (ASCO)2010;28(15 Suppl):7002. ">Ciuleanu 2010</a>). </p> </section> <section id="CD001990-sec-0086"> <h5 class="title">Tumour response</h5> <p>In <a href="./references#CD001990-bbs2-0006" title="SpiroSG , SouhamiRL , GeddesDM , AshCM , QuinnH , HarperPG , et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer1989;59:578‐83. ">Spiro 1989</a>, in the methotrexate‐doxorubicin group the partial or complete response was 22.3%; in <a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a> in the topotecan group there was no complete response and 7% showed a partial response; in <a href="./references#CD001990-bbs2-0001" title="CiuleanuT , SamarzjiaM , DemidchikY , BeliakouskiV , RancicM , BentsionDL , et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first‐line platinum‐based chemotherapy. Journal of Clinical Oncology (ASCO)2010;28(15 Suppl):7002. ">Ciuleanu 2010</a> no data were provided for picoplatin. </p> </section> <section id="CD001990-sec-0087"> <h5 class="title">Toxicity</h5> <p>No data were provided for the methotrexate‐doxorubicin group (<a href="./references#CD001990-bbs2-0006" title="SpiroSG , SouhamiRL , GeddesDM , AshCM , QuinnH , HarperPG , et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer1989;59:578‐83. ">Spiro 1989</a>). Topotecan showed more toxicity than BSC (<a href="#CD001990-tbl-0006">Table 4</a>), with 6% toxic deaths in <a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a>. In the <a href="./references#CD001990-bbs2-0001" title="CiuleanuT , SamarzjiaM , DemidchikY , BeliakouskiV , RancicM , BentsionDL , et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first‐line platinum‐based chemotherapy. Journal of Clinical Oncology (ASCO)2010;28(15 Suppl):7002. ">Ciuleanu 2010</a> study picoplatin showed more toxicity than BSC but with no deaths due to haematological toxicity (moderate‐quality evidence). </p> </section> <section id="CD001990-sec-0088"> <h5 class="title">Quality of life</h5> <p>Quality of life was not measured for patients receiving methotrexate‐doxorubicin chemotherapy in <a href="./references#CD001990-bbs2-0006" title="SpiroSG , SouhamiRL , GeddesDM , AshCM , QuinnH , HarperPG , et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer1989;59:578‐83. ">Spiro 1989</a> or for patients receiving picoplatin at relapse in <a href="./references#CD001990-bbs2-0001" title="CiuleanuT , SamarzjiaM , DemidchikY , BeliakouskiV , RancicM , BentsionDL , et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first‐line platinum‐based chemotherapy. Journal of Clinical Oncology (ASCO)2010;28(15 Suppl):7002. ">Ciuleanu 2010</a>. </p> <p><a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a> used two questionnaires: the Patient Self Assessment (PSA) questionnaire, which resembles the Lung Cancer Symptom Scale, evaluating the degree to which patients experienced nine common symptoms on a Likert scale for severity (from 1, not at all, to 4, very much); and the EuroQol‐5 Dimensions Health questionnaire (EQ‐5D), consisting of the five health status dimensions mobility, self‐care, usual activities, pain and discomfort, and anxiety and depression. The questionnaire has a rating scale from 1 (no problem) to 3 (an extreme problem), and a visual analogue scale ranking from 0 (worst imaginable health state) to 100 (best imaginable health state). Patients in both arms were evaluated before each course of second‐line chemotherapy, or at each visit in the BSC arm. Not all patients completed the pre‐specified questionnaires at the different visits. </p> <p>The difference in rate of deterioration in the score at three‐month intervals in the EQ‐5D questionnaire was significantly lower in the topotecan group (0.15, 95% CI 0.05 to 0.25). The PSA questionnaire, conducted in 61 (86%) patients in the topotecan group and 48 (69%) in the BSC group, gave significant risk ratios for shortness of breath (RR 2.18, 95% CI 1.09 to 4.38), interference with sleep (RR 2.16, 95% CI 1.15 to 4.06) and fatigue (RR 2.29, 95% CI 1.25 to 4.19) (see <a href="#CD001990-tbl-0006">Table 4</a>). </p> <p>Patients with a lower functional status based on their Eastern Cooperative Oncology Group (ECOG) performance status (<a href="./references#CD001990-bbs2-0005" title="O'BrianME , DuhMS , ChenL , AntrasL , NearyM , GrallaRJ . An analysis of disease control: is major response associated with greater symptomatic benefits than stable disease in small cell lung cancer (SCLC)? Results from the randomised Oral Topotecan (OT) vs. Best Supportive Care (BSC) trial: P1‐224. Journal of Thoracic Oncology2007;2(8):S827. ">O'Brien 2007a</a>) reported more severe symptoms in the PSA questionnaire: mean score 12.31 for ECOG 0, 16.37 for ECOG 1, and 17.58 for ECOG 2 (P = 0.0002). Mean changes from baseline in the questionnaire score showed an association between tumour response and symptom control (P = 0.0016). Patients with a partial response (n = 5) had a baseline score of 15.07, while the mean score on treatment reduced to 12.64 representing a change from baseline of ‐2.43, or 16.12% improvement in symptoms. Patients with stable disease (n = 31) did not change their score between baseline and on treatment (15.33 versus 15.35) (low‐quality evidence). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001990-sec-0089" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001990-sec-0089"></div> <p>The present study involved a comprehensive search of electronic databases and contact with authors and companies in order to identify trials that evaluated the efficacy of first‐line and second‐line chemotherapy at relapse as compared to best supportive care (BSC) or no active anticancer treatment. </p> <section id="CD001990-sec-0090"> <h3 class="title" id="CD001990-sec-0090">Summary of main results</h3> <p>Only the two studies by Kokron (<a href="./references#CD001990-bbs2-0002" title="KokronO , TitscherR , MickscheM , CerniC , WrbaH . Clinical experiences with Holoxan in small ceIl carcinoma of the bronchus (authors transl). Osterreichische Kneipp Magazin1977;15:103‐8. ">Kokron 1977b</a>; <a href="./references#CD001990-bbs2-0003" title="KokronO , MicksheM , TitscherR , WrbaH . Ifosfamide versus ifosfamide + CCNU in the treatment of inoperable small celI lung cancer. A clinical study. Onkologie1982;56:56‐9. ">Kokron 1982</a>) met the inclusion criteria for the review of first‐line chemotherapy compared with supportive care. These studies showed that for patients with extensive disease, ifosfamide gives an increased survival benefit (around 80 additional days) over supportive treatment but this benefit is not increased by the addition of CCNU. A partial tumour response of 47% was shown in the group on active therapy in the first study. Adverse effects were present in the chemotherapy group. </p> <p>The results of this review in relation to second‐line chemotherapy on relapse or at progression showed an increased survival benefit of between 63 days for patients receiving methotrexate‐doxorubicin and 84 days for patients receiving topotecan over supportive treatment. No survival benefit was shown with picoplatin over BSC. According to <a href="./references#CD001990-bbs2-0006" title="SpiroSG , SouhamiRL , GeddesDM , AshCM , QuinnH , HarperPG , et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer1989;59:578‐83. ">Spiro 1989</a>, the increase in survival after progression was significant in those patients who had previously received four cycles of first‐line chemotherapy. The pooled analysis of topotecan and picoplatin gave an HR of 0.73 (95% CI 0.55 to 0.96) and significant improvement in overall survival. <a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a> reported that the increase in survival was preserved in women, the subgroup of patients with a treatment‐free interval ≤ 60 days, patients with a performance status of 2, and in patients with liver metastases. This survival benefit was accompanied by an improvement in the quality of life, with a difference in the rate of deterioration in EQ‐5D questionnaire score at three monthly intervals significantly in favour of the topotecan group, together with an improvement in shortness of breath, interference with sleep, and fatigue in the PSA questionnaire. Tumour response (partial or complete) in the methotrexate‐doxorubicin group was 22.3%. Five patients (7%, 95% CI 2.33 to 15.67) showed a partial response in the topotecan group without any complete responses reported. </p> </section> <section id="CD001990-sec-0091"> <h3 class="title" id="CD001990-sec-0091">Overall completeness and applicability of evidence</h3> <p>The evidence that is available on the effectiveness and toxicity of first‐line chemotherapy for patients with extensive SCLC comes from two studies that compared ifosfamide and ifosfamide + CCNU versus supportive treatment (<a href="./references#CD001990-bbs2-0002" title="KokronO , TitscherR , MickscheM , CerniC , WrbaH . Clinical experiences with Holoxan in small ceIl carcinoma of the bronchus (authors transl). Osterreichische Kneipp Magazin1977;15:103‐8. ">Kokron 1977b</a>; <a href="./references#CD001990-bbs2-0003" title="KokronO , MicksheM , TitscherR , WrbaH . Ifosfamide versus ifosfamide + CCNU in the treatment of inoperable small celI lung cancer. A clinical study. Onkologie1982;56:56‐9. ">Kokron 1982</a>). It remains unclear whether the results would be the same in women, patients with poor performance status, and in patients older than 70 years. Toxic deaths due to chemotherapy as well as the balance between quality of life and life expectancy remain unclear. At the time the studies were conducted no validated instruments for measuring quality of life were available. Such instruments were first developed in the 1980s, mainly with the objective of measuring self‐perceived health in patients when the efficacy of a treatment was being evaluated (<a href="./references#CD001990-bbs2-0075" title="LacombeD . Ethical Issues in cancer clinical trials: a European Perspective. European Journal of Cancer1997;33:184‐5. ">Lacombe 1997</a>). </p> <p>Despite the methodological limitations of these trials, carried out more than 25 years ago, they seem to have provided some evidence to support Green's hypothesis (<a href="./references#CD001990-bbs2-0023" title="GreenR , HumphreyE , CloseH , PatnoM . Alkylating Agents in Bronchogenic Carcinoma. American Journal of Medicine1969;46:516‐25. ">Green 1969</a>) that first‐line chemotherapy treatment for patients with advanced SCLC produces benefits in terms of more prolonged survival. Although a large number of clinical trials comparing different regimens have been conducted in advanced SCLC, to date no consistent findings have indicated what is the most effective combination. Platinum‐based combination chemotherapy regimens have increased complete response rates with no significant benefit in survival when compared to non‐platinum chemotherapy regimens (<a href="./references#CD001990-bbs2-0055" title="AmarasenaIU , WaltersJAE , Wood‐BakerR , FongK . Platinum versus non‐platinum chemotherapy regimens for small cell lung cancer. Cochrane Database of Systematic Reviews2008, Issue 4. [DOI: 10.1002/14651858.CD006849.pub2] ">Amarasena 2009</a>), and at present are the standard first line treatment for patients with SCLC. </p> <p>The evidence available on the effectiveness of second‐line chemotherapy at relapse or progression in patients with extensive SCLC comes from three studies that compared methotrexate‐doxorubicin, topotecan, and picoplatin versus symptomatic treatment or BSC (<a href="./references#CD001990-bbs2-0001" title="CiuleanuT , SamarzjiaM , DemidchikY , BeliakouskiV , RancicM , BentsionDL , et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first‐line platinum‐based chemotherapy. Journal of Clinical Oncology (ASCO)2010;28(15 Suppl):7002. ">Ciuleanu 2010</a>; <a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a>; <a href="./references#CD001990-bbs2-0006" title="SpiroSG , SouhamiRL , GeddesDM , AshCM , QuinnH , HarperPG , et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer1989;59:578‐83. ">Spiro 1989</a>). It remains unclear whether the results would be the same in females, patients with treatment‐free interval ≤ 60 days after first‐line chemotherapy, and in patients with poor performance status. The <a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a> study showed an improvement in survival in these subgroups and no subgroup‐treatment effect interaction was reported. However, despite the fact that the trial was powered to determine the overall effect of treatment, virtually all subgroup analyses were underpowered. If a genuine subgroup‐treatment effect interaction exists, the chance of a false negative result with a statistical test of interaction will be greater than the 5% false positive rate in a trial in which no true interaction exists (<a href="./references#CD001990-bbs2-0086" title="RothwellPM . Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet2005;365:176‐86. ">Rothwell 2005</a>). Therefore, interpretation of the risks and benefits of topotecan in the subgroups should be done cautiously, and the findings need validation by replication of the data. </p> <p>The relationship between the first‐line chemotherapy received and the effect of second‐line chemotherapy remains unclear. The most commonly received first‐line chemotherapeutic agents in <a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a> and <a href="./references#CD001990-bbs2-0001" title="CiuleanuT , SamarzjiaM , DemidchikY , BeliakouskiV , RancicM , BentsionDL , et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first‐line platinum‐based chemotherapy. Journal of Clinical Oncology (ASCO)2010;28(15 Suppl):7002. ">Ciuleanu 2010</a> were cisplatin or carboplatin and etoposide, consistent with current guidelines. It has been suggested that the clinical benefit of re‐treatment correlates with the type of first‐line chemotherapy and treatment characteristics at the time of relapse (treatment‐free period), a presumption that is difficult to clarify in this study given the homogeneity of the type of first‐line chemotherapy administered to patients. </p> <p>Although treatment with picoplatin showed an improvement in the median time to progression and in the median progression‐free survival, both are surrogates outcomes for the final outcome or overall survival. A recent review (<a href="./references#CD001990-bbs2-0061" title="CianiO , BuyseM , GarsideR , PaveyT , SteinK , SterneJ , et al. Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta‐epidemiological study. BMJ2013;346:457‐69. ">Ciani 2013</a>) showed that, on average, trials using surrogate outcomes reported treatment effects that were 28% to 48% higher than trials using final relevant outcomes for patients. Surrogate trials were twice as likely to report positive treatment effects compared with the final outcome trials, and the findings were not explained by differences in risk of bias or other trial characteristics. </p> <p>The quality of life of patients receiving second‐line chemotherapy remains unclear. In this review only the topotecan study (<a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a>) addressed this question, with an improvement in shortness of breath, quality of sleep, and fatigue. </p> <p>In summary, the trials included in the review are clinically diverse and few; one of them has not been published in a peer‐reviewed journal (<a href="./references#CD001990-bbs2-0001" title="CiuleanuT , SamarzjiaM , DemidchikY , BeliakouskiV , RancicM , BentsionDL , et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first‐line platinum‐based chemotherapy. Journal of Clinical Oncology (ASCO)2010;28(15 Suppl):7002. ">Ciuleanu 2010</a>), the survival benefit is limited, a few days, and the adverse effects are present in considerable proportions. Therefore, the evidence on the benefits of second‐line chemotherapy in patients with extensive SCLC at relapse or progression is scarce, making it difficult to generate recommendations to clinicians and patients. </p> </section> <section id="CD001990-sec-0092"> <h3 class="title" id="CD001990-sec-0092">Quality of the evidence</h3> <p>The quality of the evidence available for all comparisons was moderate to very low, mainly because there were only two studies for first‐line chemotherapy and three for second‐line chemotherapy, with small sample sizes and significant risk of bias. Selection bias was considered unclear in all studies except <a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a>. Performance bias in relation to survival seemed to be at low risk of bias in all studies, although at unclear risk in relation to toxicity and quality of life. Detection bias in relation to survival was considered to be at low risk in all studies but unclear in relation to tumour response, toxicity and quality of life. Attrition bias in relation to survival was considered to be at low risk in <a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a> and unclear in the rest of studies. In relation to tumour response, toxicity and quality of life attrition bias was at a mix of low, unclear and high risk bias. Selective reporting was considered to have unclear bias in all studies except <a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a>, and four studies were considered to be affected by other bias. </p> <p>For first‐line chemotherapy the quality of the evidence for the overall survival and adverse events was very low. No evidence was found for quality of life. For second‐line chemotherapy the quality of the evidence for the overall survival and quality of life was low, and moderate for toxic deaths and adverse effects. </p> <p>In relation to other bias, the lack of information on the baseline characteristics of the treatment groups in the Kokron studies, Spiro, and Ciuleanu means that the presence of uncontrolled confounding variables cannot be excluded. Moreover, the small number of patients in each comparison group in the Kokron studies may have led to an overestimation of the effects, as has been described in other circumstances (<a href="./references#CD001990-bbs2-0080" title="MooreRA , GevaghanD , TraverMR , CollinsS , McQuayHJ . Size is everything. The impact of event rate variation on clinical trials and meta‐analysis. Pain1998;78:208‐16. ">Moore 1998</a>). The ANOVA statistical analysis in the Kokron studies is inadequate to compare mean survival between groups. As well, the Kaplan‐Meier method was inadequate and the statistical analysis should have included a Mantel‐Haenszel analysis to compare treatment groups (<a href="./references#CD001990-bbs2-0074" title="KleinbaumDG . Survival analysis: A self‐learning text. New York: Springer‐Verlag, 1996. ">Kleinbaum 1996</a>). Two trials (<a href="./references#CD001990-bbs2-0001" title="CiuleanuT , SamarzjiaM , DemidchikY , BeliakouskiV , RancicM , BentsionDL , et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first‐line platinum‐based chemotherapy. Journal of Clinical Oncology (ASCO)2010;28(15 Suppl):7002. ">Ciuleanu 2010</a>; <a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a>) were designed by the sponsors Poniard Pharmaceuticals and Glaxo‐Smith‐Kline, respectively, who held and analysed the data. Eight of the 10 authors in the O'Brien study disclosed potential conflicts of interest, all of them with the same sponsor, and the trial favoured the drug. A recent systematic review (<a href="./references#CD001990-bbs2-0078" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2012, Issue 12. ">Lundh 2012</a>) on the relationship between pharmaceutical industry sponsorship and research outcomes found that clinical trails sponsored by the pharmaceutical companies are significantly more likely than non‐commercially funded studies to report favourable efficacy and safety results and conclusions. The findings were consistent across a wide range of disease states and drugs, regardless of the type of research being assessed. The review did not find a difference in risk of bias of drugs and device trials sponsored by industry compared with non‐industry sponsored trials. However, industry sponsored trials more often had low risk of bias from blinding. Although the research methods of trials sponsored by drug companies are reported to be at least as good as or, in many cases, even better than those of non‐industry funded research, this does not guarantee the absence of bias. </p> <p>Except for the Kokron 1982 blinding was not used to evaluate the results so measurement bias for variables such as tumour response, toxicity, and quality of life cannot be excluded, although this is less important when survival is the outcome being measured (<a href="./references#CD001990-bbs2-0063" title="DaySJ , AltmanDG . Blinding in clinical trials and other studies. BMJ2000;321:504. ">Day 2000</a>). </p> <p>The attrition bias shown in the studies prevents a full intention‐to‐treat analysis being carried out (<a href="./references#CD001990-bbs2-0066" title="DumvilleJC , TorgersonDJ , HewittCE . Reporting attrition in randomised controlled trials. BMJ2006;332:969‐71. ">Dumville 2006</a>). No information on the cause of the missing data is reported, neither were there analytical methods to deal with data that are not missing at random (<a href="./references#CD001990-bbs2-0056" title="BellM , KenwardMG , FaircloughDL , HortonNJ . Differential dropout and bias in randomised controlled trials: when it matters and when it may not. BMJ2013;346:e8668. ">Bell 2013</a>). </p> <p>The major strength of the review is that it is a comprehensive analysis of all the studies undertaken on the subject. The major limitation is the scarce number of studies included, the unclear risk of bias in the first‐line chemotherapy studies and the majority of second‐line chemotherapy studies, except for only one study that was judged to be at low risk of bias in some aspects such as allocation concealment, performance and detection of survival, attrition and outcome reporting (<a href="./references#CD001990-bbs2-0004" title="O'BrienMER , CiuleanuTE , TsekovH , ShparykY , CuceviaB , JuhaszG , et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. Journal of Clinical Oncology2006;24:5441‐7. ">O'Brien 2006</a>). Given the paucity of available robust studies assessing the clinical effects of first‐line chemotherapy and second‐line chemotherapy at relapse or progression over BSC, the evidence is insufficient to judge the effectiveness and safety of chemotherapy for the treatment of extensive SCLC with the desired degree of precision. </p> </section> <section id="CD001990-sec-0093"> <h3 class="title" id="CD001990-sec-0093">Potential biases in the review process</h3> <p>There was no language restriction in the search for trials and trial selection. Pharmaceutical companies were contacted for supplementary data on any non‐published studies but no answer was received so publication bias could not be excluded. Conference abstracts were not searched. Given the few trials included in the review, no funnel plot could be drawn. </p> </section> <section id="CD001990-sec-0094"> <h3 class="title" id="CD001990-sec-0094">Agreements and disagreements with other studies or reviews</h3> <p>We did not find any systematic review of first‐line chemotherapy treatment in advanced SCLC to compare with the results of this review with. In spite of limited evidence concerning the benefits of first‐line chemotherapy, many would now consider it unethical not to give chemotherapy to patients with advanced SCLC. </p> <p>According to a few studies, it seems that patients with advanced disease and poor prognostic factors (brain metastases, low performance status, biochemical anomalies such as increased lactate dehydrogenase (LDH), alkaline phosphatase, and sodium anomalies) have a higher mortality during the first chemotherapy cycle as a consequence of toxicity (<a href="./references#CD001990-bbs2-0057" title="BernhardJ , HürnyC , BacchiM , JossRA , CavalliF , SennHJ , et al. Initial prognostic factors in small‐celI lung cancer patients predicting quality of life during chemotherapy. British Journal of Cancer1996;74:1660‐7. ">Bernhard 1996</a>; <a href="./references#CD001990-bbs2-0083" title="RawsonNS , PetoJ . An overview of prognostic factors in small cell Lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. British Journal of Cancer1990;61:597‐604. ">Rawson 1990</a>; <a href="./references#CD001990-bbs2-0088" title="SouhamiRL , MorittuL , AshCM , EarIH , GeddesD , HarperPG , et al. Identification of patients at high risk of chemotherapy induced toxicity in SCLC. Antibiotics and Chemotherapy1988;41:220‐5. ">Souhami 1988</a>). None of the studies included in this review reported on the number of early deaths due to chemotherapy in patients with a poor prognosis. So the benefits of first‐line chemotherapy in patients with poor prognosis remain unclear. </p> <p>We did find four reviews of second‐line chemotherapy in SCLC patients at relapse or progression to compare with the results of this review. The <a href="./references#CD001990-bbs2-0087" title="SeidenfeldJ , Samson DJ , BonnellCJ , ZieglerKM , AronsonN . Management of small cell lung cancer. Evidence Report/Technology Assessment No 143. AHRQ Publication No. 06‐E016. Rockville, MD: Agency for Health Research and QualityJuly 2006. ">Seidenfeld 2006</a> evidence report made reference to two studies included in this review with the same conclusions as in our review. <a href="./references#CD001990-bbs2-0059" title="ChengS , EvansWK , Stys‐NormanD , ShepherdFA , the Lung Cancer Disease Site Group of Cancer Care Ontario' Program in Evidence‐based Care. Chemotherapy for relapse small cell lung cancer: a systematic review and practice guideline. Journal of Thoracic Oncology2007;2:348‐54. ">Cheng 2007</a> included only the trial of O'Brien, with results similar to our review. <a href="./references#CD001990-bbs2-0085" title="RiemsmaR , SimonsJP , BashirZ , GoochCL , kleijnenJ . Systematic review of topotecan (Hycamtin) in relapsed small cell lung cancer. BMC Cancer2010;10:436‐48. ">Riemsma 2010</a> included the O'Brien study and six other studies outside the inclusion criteria of this review, with similar findings to our review. <a href="./references#CD001990-bbs2-0077" title="LovemanE , JonesJ , HartwellD , BirdA , HarrisP , WelchK , CleggA . The clinical effectiveness and cost‐effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation. Health Technological Assessment2010;14(19):1‐6. ">Loveman 2010</a> developed an economic model to estimate the cost‐effectiveness of oral or intravenous topotecan compared with BSC for patients with relapsed SCLC for whom re‐treatment with the first‐line regimen was not considered appropriate. It included the O'Brien study and four other trials outside the scope of this review. The cost difference gave an incremental cost‐effectiveness ratio (ICER) of GBP 26,833 per QALY gained. </p> <p>Benefit of first‐line chemotherapy was shown in <a href="./references#CD001990-bbs2-0091" title="Sundstr¢mS , BremnesRM , KaasaS , Aaseb¢U , AamdalS . Second‐line chemotherapy in recurrent small lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP‐regimen) or cyclophosphamide, epirubicin, and vincristin (CEV‐regimen). Lung Cancer2005;48:251‐61. ">Sundstr¢m 2005</a>, an observational study that reported a survival benefit in favour of the chemotherapeutic group in comparison with supportive care (5.3 and 2.2 months, respectively). </p> <p>However, no survival benefit was found for second‐line chemotherapy in the retrospective <a href="./references#CD001990-bbs2-0073" title="KimYH , GotoK , YohK , NihoS , OhmatsuH , KubotaK , et al. Performance status and sensitivity to first‐line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second‐line chemotherapy. Cancer2008;113:2518‐23. ">Kim 2008</a> study in which disease recurrence was more than three months compared with disease recurrence within three months without the chemotherapy. </p> <p>The unclear benefit of second‐line chemotherapy in women that was found in this review with topotecan has been remarked on by <a href="./references#CD001990-bbs2-0093" title="Wheatley‐PriceP , MaC , AshcroftLF , NankivellM , StephensRJ , WhiteSC , et al. The strength of female sex as prognostic factor in small‐cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit. Annals of Oncology2010;21:232‐7. ">Weatley‐Price 2010</a> in a pooled analysis of chemotherapy trials, although at the same time the women experienced greater levels of grade 3/4 emesis. </p> <p>The treatments in the studies of this review were administered intravenously and thus it was not possible to evaluate the benefit of oral chemotherapy over BSC. Yet oral administration is preferred by patients over intravenous therapies, including in the case of topotecan (<a href="./references#CD001990-bbs2-0068" title="GrallaRJ . Quality of life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life. The Oncologist2004;9 Suppl 6:14‐24. ">Gralla 2004</a>). </p> <p>The effectiveness of intense follow‐up after a response in patients with SCLC treated with first‐line chemotherapy has not been addressed in this review. However, an evaluation study (<a href="./references#CD001990-bbs2-0090" title="SugiyamaT , HiroseT , HosakaT , KusumotoS , NakashimaM , YamaokaT , et al. Effectiveness of intensive follow‐up after response in patients with small cell lung cancer. Lung Cancer2008;59:255‐61. ">Sugiyama 2008</a>) reported that survival was significantly longer in an intense follow‐up arm (MD 9 months, 95% CI 7 to 12 months) than in the non‐intensive arm (4 months, 95% CI 2 to 7 months). </p> <p>Given the poor prognosis of extensive SCLC and the report that 69% of patients with extensive lung cancer have inaccurate expectations about the benefits of chemotherapy that are not consistent with their life expectancy (<a href="./references#CD001990-bbs2-0094" title="WeeksJC , CatalanoPJ , CroninA , FinkelmanMD , MackJW , KeatingNL , et al. Patients' expectations about effects of chemotherapy for advanced cancer. New England Journal of Medicine2012;367:1616‐25. ">Weeks 2012</a>), this misunderstanding could represent an obstacle in optimal end‐of‐life planning and care. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001990-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/media/CDSR/CD001990/urn:x-wiley:14651858:media:CD001990:CD001990-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/media/CDSR/CD001990/image_t/tCD001990-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD001990-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001990.pub3/media/CDSR/CD001990/image_n/nCD001990-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/full#CD001990-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/media/CDSR/CD001990/image_n/nCD001990-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001990-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/media/CDSR/CD001990/urn:x-wiley:14651858:media:CD001990:CD001990-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/media/CDSR/CD001990/image_t/tCD001990-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001990-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001990.pub3/media/CDSR/CD001990/image_n/nCD001990-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/full#CD001990-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/media/CDSR/CD001990/image_n/nCD001990-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001990-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/media/CDSR/CD001990/urn:x-wiley:14651858:media:CD001990:CD001990-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/media/CDSR/CD001990/image_t/tCD001990-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001990-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001990.pub3/media/CDSR/CD001990/image_n/nCD001990-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/full#CD001990-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/media/CDSR/CD001990/image_n/nCD001990-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001990-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/media/CDSR/CD001990/urn:x-wiley:14651858:media:CD001990:CD001990-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/media/CDSR/CD001990/image_t/tCD001990-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Second‐line chemotherapy at relapse versus BSC, outcome: 1.1 Overall survival." data-id="CD001990-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001990.pub3/media/CDSR/CD001990/image_n/nCD001990-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Second‐line chemotherapy at relapse versus BSC, outcome: 1.1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/full#CD001990-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/media/CDSR/CD001990/image_n/nCD001990-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001990-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/media/CDSR/CD001990/urn:x-wiley:14651858:media:CD001990:CD001990-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/media/CDSR/CD001990/image_t/tCD001990-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Second‐line chemotherapy at relapse versus best supportive care (BSC), Outcome 1 Overall survival." data-id="CD001990-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001990.pub3/media/CDSR/CD001990/image_n/nCD001990-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Second‐line chemotherapy at relapse versus best supportive care (BSC), Outcome 1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/references#CD001990-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/media/CDSR/CD001990/image_n/nCD001990-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001990-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">First‐line chemotherapy compared with BSC for extensive SCLC</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>First‐line chemotherapy compared with BSC for extensive SCLC</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: patients</b> with extensive SCLC without previous treatment </p> <p><b>Settings: one hospital in Vienna</b> </p> <p><b>Intervention: first‐line chemotherapy</b> </p> <p><b>Comparison: Supportive treatment</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Supportive care</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>First‐line chemotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean survival ranged across control groups from<br/> 56‐93 days <sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean survival in the intervention groups was<br/> 134‐172 days <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Haematological: 0%</p> <p>Leucopenia:0%</p> <p>Vomiting and hair loss: 0%</p> <p>Other: 0%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Haematological:   94.1%</p> <p>Leucopenia:15% ifosfamide; 15.8% ifosfamide + CCNU</p> <p>Vomiting and hair loss: 70% ifosfamide; 68.4% ifosfamide + CCNU</p> <p>Other: 55% ifosfamide; 52.6% ifosfamide + CCNU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. The corresponding median survival time in extensive SCLC in the control and intervention groups has been obtained from Kokron 1977 and Kokron 1982 </p> <p>2. Significant risk of bias across the studies</p> <p>3. Small sample sizes across the studies</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">First‐line chemotherapy compared with BSC for extensive SCLC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/full#CD001990-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001990-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Second‐line chemotherapy at relapse or progression in extensive SCLC</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Second‐line chemotherapy compared with BSC for extensive SCLC</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: patients</b> with extensive SCLC who relapsed or progressed after first‐line chemotherapy </p> <p><b>Settings: multi‐institutional‐multicentre</b> </p> <p><b>Intervention: second‐line chemotherapy</b> </p> <p><b>Comparison: BSC</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>BSC</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Second‐line chemotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median survival ranged across control groups from 97.3‐138 days<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median survival in the intervention groups was 144‐181.3 days<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0.73</p> <p>(0.55, 0.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>542</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Toxic death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6% topotecan</p> <p>0% picoplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>542</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Dyspnoea 3%</p> <p>Fatigue 4%</p> <p>Non sepsis infection 12%</p> <p>sepsis 1%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Haematological: 18%‐61% neutropenia, 38%‐41% Thrombocytopenia, 25%‐29% anaemia,</p> <p>Non sepsis infection 14%</p> <p>Sepsis 4%</p> <p>Asthenia 11%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>542</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See footnotes 3</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See footnotes 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Difference in rate of deterioration per 3‐month intervals in the EQ‐5D score: 0.15 (95% CI 0.05, 0.25) </p> <p>In the PSA questionnaire:</p> <p>shortness of breath RR: 2.18 (1.09 to 4.38)</p> <p>interference with sleep RR: 2.16 (1.15 to 4.06)</p> <p>fatigue RR: 2.29 (1.25 to 4.19)<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>4,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>BSC:</b> best supportive care; <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>HR</b>: hazard ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. The corresponding median survival time in extensive SCLC in the control group has been obtained from O'Brien 2006 and Ciuleanu 2010 </p> <p>2. The corresponding median survival time in extensive SCLC in the intervention group has been obtained from O'Brien 2006 and Ciuleanu 2010 </p> <p>3. The difference in rate of deterioration was obtained through the EQ‐5D (EuroQol‐5‐Dimensions Health) questionnaire, consisting of five health status dimensions: mobility, self‐care, usual activities, pain and discomfort, anxiety and depression, with rating of 1 (no problem) to 3 (extreme problem). Patients were evaluated before each course of second‐line chemotherapy, or at each visit in the BSC arm. </p> <p>The PSA (Patient Self Assessment) questionnaire rating scale for severity is from 1 (not at all), to 4 (very much) </p> <p>4. Some significant risk of bias across the studies</p> <p>5. Some significant risk of other bias in one study</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Second‐line chemotherapy at relapse or progression in extensive SCLC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/full#CD001990-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001990-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">First‐line chemotherapy versus best supportive care (BSC)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group A</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group B</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group C</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kokron 1977b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Supportive care: mainly antibiotics and analgesics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ifosfamide monotherapy: 1500 mg/m<sup>2</sup> ifosfamide </p> <p>as short infusion iv. on day 1, followed by ifosfamide</p> <p>1000 mg/m<sup>2</sup> iv.on days 2 and 3. Repetition of ifosfamide </p> <p>1000 mg/m<sup>2</sup> iv on days 8, 9, 10 and 15,16,17. </p> <p>Continuation of the therapy after six weeks with three day therapy (1000 mg/m<sup>2</sup> daily each). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kokron 1982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No active anticancer treatment: infusion of Ringers solution 1000 ml + 1 gr vitamin C iv three times a week during an in‐patient stay. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ifosfamide monotherapy: same schedule as the first study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ifosfamide + CCNU (chloroethyl‐cyclohexyl‐nitrosourea):</p> <p>ifosfamide therapy as described under Group B,</p> <p>in addition to CCNU 60 mg/m<sup>2</sup> on day 1 with repetition after six weeks. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">First‐line chemotherapy versus best supportive care (BSC)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/full#CD001990-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001990-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Second‐line chemotherapy at relapse versus best supportive care (BSC)</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group A</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group B</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spiro 1989*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Symptomatic treatment including palliative irradiation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methotrexate 50 mg/m<sup>2</sup> iv plus doxorubicin 50 mg/m<sup>2</sup> iv, repeated every </p> <p>three weeks with a maximum of nine courses</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>O'Brien 2006**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BSC<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Topotecan in capsules containing the equivalent to 0.25 mg, doses</p> <p>2.3 mg/m<sup>2</sup> on days 1 to 5 every 21 days, at least four cycles + BSC. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ciuleanu 2010***</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BSC<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Picoplatin 150 mg/m<sup>2</sup>, every 3 weeks median cycles 3 </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>*Patients with disease progression. First‐line chemotherapy treatment consisted of either four or eight cycles of cyclophosphamide 1 g/m<sup>2</sup> iv; vincristine 1.4 mg/m<sup>2</sup> iv; on day 1, and etoposide capsules 100 mg orally eight hourly on days 1 to 3, every 21 days </p> <p>**Patients with relapse and who were unsuitable for further intravenous chemotherapy</p> <p>***Patients with refractory disease or progression within six months after first‐line platinum‐based chemotherapy </p> <p>a = Best Supportive Care</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Second‐line chemotherapy at relapse versus best supportive care (BSC)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/full#CD001990-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001990-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Results of the studies included in the review (first‐line chemotherapy versus best supportive care (BSC)</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> <p><b>ID</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Objective</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Survival</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tumour response</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Toxicity</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Kokron 1977b</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To compare supportive care vs Ifosfamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MST<sup>1:</sup> supportive care group = 93 days vs 172 Ifosfamide group (range:11 to 544 vs 1 to 1096) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PR<sup>2</sup> = 0%  supportive care group vs 47% Ifosfamide group </p> <p>CR<sup>3</sup>= 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haematological: 0%  supportive care group vs  94.1% Ifosfamide group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Kokron 1982</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To compare no active anticancer treatment vs ifosfamide vs Ifosfamide + CCNU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MST: in extensive disease: no active anticancer treatment = 56 days vs 134 Ifosfamide vs 122 Ifosfamide + CCNU. Grouped data: no active anticancer treatment, median = 161.5 (MST = 208.4), Ifosfamide, median = 341 (MST = 348.5), Ifosfamide + CCNU, median = 252 (MST = 322.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grouped data (extensive and limited disease): CR = 1.9% Ifosfamide; PR = 16.9 Ifosfamide, and 13.2% Ifosfamide + CCNU </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grouped data: leucopenia:0% no active anticancer treatment; 15% Ifosfamide; 15.8% Ifosfamide + CCNU. Vomiting and hair loss: 0% no active anticancer treatment, 70% Ifosfamide; 68.4% Ifosfamide + CCNU. Other: 0% no active anticancer treatment; 55% Ifosfamide; 52.6% Ifosfamide + CCNU </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>MST = mean survival time; PR = partial response; CR = complete response; CCNU = cyclohexylnitrosourea</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Results of the studies included in the review (first‐line chemotherapy versus best supportive care (BSC)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/full#CD001990-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001990-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Results of the studies included in the review (second‐line chemotherapy versus best supportive care (BSC)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> <p><b>ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Objective</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Survival</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tumour response</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Toxicity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Spiro 1989</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To assess the effects of duration of chemotherapy on survival, <i>and</i> at relapse, the effects of further chemotherapy compared with symptomatic treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MST<sup>1</sup>: symptomatic = 77 to 84 days vs 140 to 105 days methotrexate‐doxorubicin group (<i>in previous chemotherapy: 4 cycles‐8 cycles, vs 4 cycles‐8 cycles)</i> Only significant 77 vs 140 days (P &lt; 0.001) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PR<sup>2</sup> or CR<sup>3</sup> in methotrexate‐doxorubicin group = 22.3% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not provided for second‐line chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>O'Brien 2006</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>To define risk and benefit of second‐line chemotherapy at relapse vs BSC in patients unsuitable for standard intravenous chemotherapy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MST: in BSC 97.3 days (95% CI, 77.7 to 130.2) vs  181.3 days (95% CI, 128.1 to 221.2) in Topotecan group (log‐rank P = 0.01) </p> <p><i>Subgroup analysis</i> </p> <p>a) treatment‐free interval &lt;=60 days of first‐line chemotherapy: topotecan 163.1 (95% CI 74.9 to 216.3) vs BSC 92.4 (95% CI 49 to 147) </p> <p>b) performance status 2: topotecan 146.3 (93.8 to 188.3) vs BSC 53.9 (37.1 to 91.7)</p> <p>c) female: HR 0.38 (95% CI 0.18 to 0.76)</p> <p>d) liver metastasis: HR 0.58 (95% CI 0.38 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PR  in the topotecan group = 7% (95% CI, 2.33 to 15.67)</p> <p>CR 0%</p> <p>In treatment‐free interval &lt;=60 days: PR 18% (5.2 to 40.3) vs 2% 80.05 to 10.9) in treatment‐free interval &gt;60 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topotecan group: <i>Haematological</i>: neutropenia ¾, 61%; thrombocytopenia ¾, 38%, anaemia ¾, 25%. Nonsepsis infection&gt;= grade 2, 14%, vs 12% in BSC. Sepsis 4% in topotecan vs 1% in BSC. </p> <p><i>Non‐haematologica</i>l 3/4 in topotecan vs BSC: dyspnoea 3% vs 9%; fatigue 4% vs 4%. </p> <p>Toxic deaths in topotecan: 6%</p> <p>all‐cause mortality within 30 days: 7% topotecan vs 13% BSC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Difference in rate of deterioration per 3‐month intervals in EQ‐5D was 0.15 (95% CI 0.05 to 0.25) </p> <p>In PSA questionnaire:</p> <p>shortness of breath RR 2.18 (1.09 to 4.38)</p> <p>interference with sleep 2.16 (1.15 to 4.06)</p> <p>fatigue 2.29 (1.25 to 4.19)</p> <p>All in favour of topotecan</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ciuleanu 2010</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>To assess survival of patients treated with second‐line chemotherapy who were refractory or who progressed within six months of first‐line platinum‐based chemotherapy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MST: in BSC 138 days (95% CI 112 to 168)</p> <p>in picoplatin 144 days (95% CI 133 to 175)</p> <p>HR: 0.817 95% CI 0.65 to 1.03 (P=0.00895)</p> <p>Time to progression:79 days picoplatin, 47 days BSC</p> <p>HR: 0.610 (P=0.0002)</p> <p>Median progression‐free survival: 63 days picoplatin, 46 days BSC</p> <p>HR: 0.783 (P=0.0281)</p> <p><i>Subgroup analysis</i> </p> <p>a) patients who did not receive chemotherapy post‐study (273: 194 picoplatin vs 79 BSC): picoplatin 128 days (95% CI 112 to 140), BSC 101 (77 to 140), HR 0.730 (P=0.0345) </p> <p>b) patients refractory or relapsed within 45 days of first‐line chemotherapy (294: 202 picoplatin vs 92 BSC): </p> <p>picoplatin 149, BSC 129,</p> <p>HR 0.717 (P=0.0173)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Picoplatin group: <i>Haematological</i>: 3/4 in &gt;10%: </p> <p>44% thrombocytopenia</p> <p>29% anaemia</p> <p>18% neutropenia</p> <p>&lt;1% febrile neutropenia</p> <p>No deaths to haematological toxicity, no bleeding</p> <p><i>Nonhaematological</i>: </p> <p>0.8% grade 3 neuropathy</p> <p>11% asthenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>MST = median survival time; PR = partial response CR = complete response; BSC = best support care; CI = confidence interval; EQ‐5D = EuroQol‐5‐Dimensions (mobility, self‐care, usual activities, pain and discomfort, anxiety and depression) with rating 1 (no problem) to 3 (extreme problem); PSA = Patient Self Assessment questionnaire, with rating 1 (not at all) to 4 (very much) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Results of the studies included in the review (second‐line chemotherapy versus best supportive care (BSC)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/full#CD001990-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001990-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Second‐line chemotherapy at relapse versus best supportive care (BSC)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.55, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Second‐line chemotherapy at relapse versus best supportive care (BSC)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001990.pub3/references#CD001990-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001990.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD001990-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001990-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD001990-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD001990-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD001990-note-0002">한국어</a> </li> <li class="section-language"> <a class="" href="pt#CD001990-note-0001">Português</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001990\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001990\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001990\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001990\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001990\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001990\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001990\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001990\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001990\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001990\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001990\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001990\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001990\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001990\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001990\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001990\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001990\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001990\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=STpJR8yz&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001990.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001990.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001990.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001990.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001990.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714684797"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001990.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714684801"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001990.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d74b1dba8937f',t:'MTc0MDcxNDY4NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 